Tobacco-related morbidity and mortality continue to be a significant public health concern. Unfortunately, current FDA-approved smoking cessation pharmacotherapies have limited efficacy and are associated with high rates of relapse. Therefore, a better understanding of the neurobiological and neurophysiological mechanisms that promote smoking relapse is needed to develop novel smoking cessation medications. Here, we review preclinical studies focused on identifying the neurotransmitter and neuromodulator systems that mediate nicotine relapse, often modeled in laboratory animals using the reinstatement paradigm, as well as the plasticity-dependent neurophysiological mechanisms that facilitate nicotine reinstatement. Particular emphasis is placed on how these neuroadaptations relate to smoking relapse in humans. We also highlight a number of important gaps in our understanding of the neural mechanisms underlying nicotine reinstatement and critical future directions, which may lead toward the development of novel, target pharmacotherapies for smoking cessation.

Approximately 16% of American adults smoke traditional cigarettes, and the prevalence of noncombustible tobacco use is rising dramatically. The use of electronic cigarettes (e-cigarettes) has tripled in middle- and high-school students in the United States in the last 4 years [1, 2]. Tobacco smoking remains the leading cause of preventable death in the United States, accounting for approximately 1 out of every 5 deaths annually [3]. On average, smokers die 13.5 years earlier than nonsmokers [4] and cigarette smoking-related illnesses cost more than USD 300 billion annually in the United States (i.e., USD 156 billion in lost productivity and USD 170 billion in health care expenditures) [5]. While smoking cessation at any age significantly increases life expectancy [6], only 3% of smokers are able to quit successfully on their own [7]. The majority of smokers who relapse do so during the first week of a quit attempt [8, 9]. Unfortunately, current FDA-approved medications for smoking cessation have modest efficacy and are associated with high rates of relapse [10]. Thus, there is a critical need to develop novel and more effective smoking cessation pharmacotherapies. Successful development of novel smoking cessation medications requires translational studies that advance and accelerate preclinical findings into pilot clinical trials [11, 12]. Preclinical studies utilizing rodent models of addiction-like behaviors are critical towards identifying molecular substrates that could serve as targets for new smoking cessation pharmacotherapies. Indeed, this drug discovery process can be guided by an improved understanding of the neurobiology that mediates smoking relapse.

Nicotine is the principal psychoactive chemical in tobacco that mediates the reinforcing effects of cigarette smoking and other forms of tobacco [13-17]. Therefore, the vast majority of biomedical research investigating the neurobiological and neurophysiological bases of smoking cessation focuses primarily on nicotine – although more recent studies have begun to investigate the role of other tobacco constituents and byproducts [18-23]. Intravenous drug self-administration in laboratory animals and humans is a behavioral paradigm used commonly to measure the reinforcing efficacy of nicotine [24, 25]. Nicotine self-administration has the highest degree of face validity of all animal models of nicotine addiction, primarily because it mimics voluntary tobacco consumption in humans [25]. Therefore, the drug self-administration model is a critical component of key studies examining the neural mechanisms underlying voluntary nicotine taking and seeking in rodents [24, 26, for review see,27, 28]. While nicotine self-administration studies in human subjects typically involve cigarette-smoking behavior, the majority of nicotine self-administration studies in rodents entail intravenous administration immediately following an operant response (i.e., lever press or nose poke). Intravenous self-administration is used primarily because this route simulates the rapid rise in arterial nicotine and rapid distribution of nicotine into the brain that occurs via the typical pulmonary route of exposure in humans [29]. Plasma nicotine levels are similar in animals self-administering nicotine and human tobacco smokers, further validating this animal model of nicotine addiction [30]. In addition, the predictive validity associated with altered nicotine self-administration and the effectiveness of smoking cessation medications appears to be relatively high [11]. For example, all three FDA-approved treatments for smoking cessation (i.e., varenicline, nicotine replacement therapies, and bupropion) decrease nicotine self-administration in rodents [31-33]. Finally, it is thought that nicotine self-administration has good construct validity as an emerging literature indicates that similar changes in dopaminergic, cholinergic, GABAergic, glutamatergic, serotonergic, and cannabinoid systems mediate the reinforcing effects of nicotine in both humans and laboratory animals [25].

Smoking relapse is typically modeled in animals using the nicotine self-administration/extinction/reinstatement paradigm. Briefly, nicotine seeking can be reinstated after a period of nicotine self-administration and the subsequent extinction of the drug-reinforced behavior. The same stimuli that precipitate smoking relapse (i.e., stress, exposure to drug-associated stimuli and re-exposure to the drug itself) during periods of abstinence in humans can be used to reinstate nicotine-seeking behavior in rodents [34-36]. For example, following extinction of nicotine self-administration, systemic injections of relatively low doses of nicotine and/or cues previously paired with nicotine taking reinstate operant responding in the absence of nicotine reinforcement in rodents [37, 38]. The validity of the nicotine reinstatement model as an in vivo medication screen appears promising for smoking relapse [39]. Indeed, varenicline, an FDA-approved smoking cessation pharmacotherapy, attenuates the reinstatement of nicotine seeking in rats [40, 41] as well as smoking relapse in humans [42]. However, despite robust effects on nicotine reinstatement in rats, the efficacy of smoking cessation pharmacotherapies (i.e., varenicline and bupropion) in humans remains modest. This is likely due to the complexity of smoking behavior and relapse in humans as well as an incomplete understanding of the neurobiological mechanisms underlying relapse. It is important to note that the reinstatement paradigm, which is used to model relapse in human smokers, does not require nicotine dependence, as measured by somatic signs of physical withdrawal. Therefore, it is possible that some of the neuroadaptations that underlie smoking relapse are distinct from the mechanisms mediating physical withdrawal from nicotine. This presents a distinct advantage of preclinical research aimed at identifying specific neuroadaptations that promote or facilitate nicotine-seeking behavior and smoking relapse. However, the lack of physical dependence also highlights a potential limitation, as nicotine seeking in humans is likely due to both avoidance of withdrawal syndrome and relapse mechanisms. Thus, this is a consideration of preclinical studies of nicotine seeking that requires additional attention.

To better understand the mechanisms mediating nicotine addiction-like behaviors, including relapse, several researchers have investigated nicotine-mediated changes in neurophysiology and plasticity using in vitro biochemical, electrochemical, and electrophysiological preparations [43-47]. The goal of this article is to review an emerging literature examining the neurotransmitter systems and the plasticity-dependent neurobiological and neurophysiological mechanisms underlying nicotine-seeking behavior in rodents, particularly as it relates to relapse in human smokers. We will also highlight important areas of consideration for future investigations. A more complete understanding of how nicotine-induced neuroadaptations alter neural circuits to produce nicotine-seeking behavior could lead to the development of novel, targeted pharmacotherapies for smoking cessation.

Nicotine reinforcement is mediated through different neurotransmitter systems, and many investigations of nicotine-seeking behavior (in animal models) and relapse behavior (in human smokers) have focused on neurotransmitter mechanisms of drug-taking and drug-seeking behavior. The reinforcing effects of nicotine are mediated, in large part, by activation of neuronal nicotinic acetylcholine receptors (nAChRs) in the mesoaccumbens dopamine pathway [26, 48, 49]. Indeed, systemic administration of nicotine increases extracellular dopamine levels in the nucleus accumbens (NAc) [50-52], specifically in the shell subregion [53]. Moreover, direct infusions of nicotine into the ventral tegmental area (VTA) [52, 54] and NAc [54, 55] also increase dopamine release in the accumbens. Furthermore, acute and chronic nicotine exposures produce dynamic changes in dopamine levels in the NAc that are associated with nicotine reinforcement [53, 56]. The ability of nicotine to activate mesoaccumbens dopamine projections relies on β2-containing nAChRs expressed on VTA dopamine neurons [57] and α7* nAChRs (* indicates the possible presence of additional, unidentified subunit[s]) expressed on glutamatergic afferents in the VTA [43]. There is clear evidence that neuronal α4β2* nAChRs (* indicates the possible presence of additional subunits) play a critical role in nicotine reinforcement [26, 58, 59], which also supports the utility of the ongoing development of novel smoking cessation pharmacotherapies targeting this receptor population. It is also clear that glutamate transmission in the brain plays a critical role in nicotine addiction [60-62]. Specifically, nicotine exposure increases extracellular glutamate levels in the VTA [63] and promotes excitatory tone in the VTA, both of which can enhance dopamine cell firing to facilitate nicotine reinforcement. Given this literature, many studies of nicotine seeking and smoking relapse have focused on dopaminergic, cholinergic, and glutamatergic mechanisms [36, 60]. However, more recent studies reveal novel roles for other neurotransmitter and neuropeptide mechanisms. In this section, we will review how these systems contribute to nicotine seeking in rats, and possibly to relapse behavior in humans.

Dopamine

As noted above, nicotine effects on the mesolimbic reward system, and on dopamine transmission in particular, are known to mediate nicotine reinforcement. There are five dopamine receptor subtypes classified as D1-like (D1 and D5) or D2-like (D2, D3, and D4), based on sequence homology and pharmacology [64-66]. Systemic administration of either a D1-like or D2-like dopamine receptor antagonist is sufficient to reduce cue-induced reinstatement of nicotine seeking [67]. While these findings indicate that dopamine receptors play an important role in nicotine seeking, they do not identify roles for individual dopamine receptor subtypes in the reinstatement of nicotine seeking. Importantly, however, human genetics studies have identified single nucleotide polymorphisms in the dopamine D4 receptor gene that correlate with cue reactivity in human smokers [68-70]. The systemic administration of a dopamine D4 receptor antagonist attenuates both cue- and nicotine-induced reinstatement of drug seeking [71]. These findings suggest that dopamine D4 receptors could serve as potential targets for novel smoking cessation pharmacotherapies. In addition to these dopamine D4 receptor-mediated effects, systemic administration of selective dopamine D3 receptor antagonists reduces drug-seeking behavior elicited by either an acute priming injection of nicotine [72, 73] or re-exposure to conditioned stimuli that were paired with nicotine taking prior to withdrawal [74]. Repeated systemic nicotine administration produces locomotor sensitization, which is associated with increased expression of dopamine D3, but not D1 and D2, receptor subtypes in the NAc shell [75]. Dopamine D3 receptors are expressed at high levels in the NAc shell, specifically in medium spiny GABAergic projection neurons [76-78]. However, it is not clear if similar D3 mechanisms in the accumbens mediate nicotine seeking during abstinence. Recent evidence indicates that pharmacological blockade of dopamine D3 receptors in the basolateral amygdala (BLA) and lateral habenula, but not the NAc, regulate the reinstatement of nicotine-seeking behavior [74]. Thus, future studies are required to identify the precise role of dopamine receptor subtypes in neurocircuits known to mediate nicotine seeking.

Endogenous fatty acid amides function as ligands of alpha-type peroxisome proliferator-activated receptors (PPAR-α) and are metabolized by fatty acid amide hydrolase (FAAH). Inhibition of FAAH prevents nicotine-induced elevations in extracellular dopamine levels in the NAc shell and reduces nicotine-induced excitation of VTA dopamine neurons [79, 80]. Moreover, pharmacological inhibition of FAAH attenuates nicotine seeking, and these effects are due, in part, to activation of PPAR-α [80, 81]. Consistent with the effects of FAAH inhibitors, PPAR-α agonists decrease nicotine-induced excitation of VTA dopamine neurons, thereby blocking nicotine-induced dopamine release in the NAc shell, and attenuate nicotine- and cue-induced reinstatement of nicotine-seeking behavior [82, 83]. These data indicate that activating PPAR-α is sufficient to prevent nicotine seeking by decreasing dopaminergic tone.

Glutamate

Several pieces of evidence point to a strong role for glutamatergic mechanisms underlying nicotine-seeking behavior. For example, extracellular glutamate levels in the NAc increase following cue-induced nicotine reinstatement [84]. Additionally, nicotine-seeking behavior is associated with changes in the cystine-glutamate exchanger, a heterodimeric protein complex that regulates extrasynaptic glutamate levels [85]. Specifically, withdrawal following voluntary nicotine taking reduces expression of the catalytic subunit (xCT) of the cystine-glutamate exchanger in the VTA and NAc [86]. Together, these results suggest that reversing or restoring nicotine-induced decreases in extracellular glutamate levels in the brain may prevent the reinstatement of nicotine-seeking behavior. However, strategies aimed at increasing extracellular glutamate levels in the brain during nicotine withdrawal have produced mixed effects on nicotine-seeking behavior. For example, systemic administration of N-acetylcysteine, a cystine pro-drug that increases the activity of the xCT resulting in increased extracellular glutamate levels, has been shown to attenuate [87] or have no effect [88] on the reinstatement of nicotine seeking. With regard to the clinical literature, N-acetylcysteine does not produce a therapeutically robust response in human smokers. For example, N-acetylcysteine decreases self-reported number of cigarettes smoked per day but does not produce concurrent reductions in breath carbon monoxide levels and fails to prevent relapse in human smokers [86, 89]. Thus, the efficacy of N-acetylcysteine in reducing nicotine seeking in both rodents and humans appears weak at best.

At the receptor level, withdrawal following repeated nicotine taking is associated with increased glutamate receptor expression. Specifically, nicotine withdrawal increased protein expression of AMPA receptor GluA1 subunits and NMDA receptor GluN2A and GluN2B subunits, as well as reduced protein expression of the glutamate transporter-1 in the NAc core [84, 86]. Pharmacological inhibition of GluN2A- and GluN2B-containing NMDA receptors in the NAc core decreases cue-induced reinstatement of nicotine seeking [84]. Interestingly, a nonselective NMDA receptor antagonist increases cue-induced nicotine seeking when infused directly into the NAc core [90]. It is hypothesized that this increase in drug seeking when NMDA receptors are inhibited is due, in part, to activation of non-NMDA glutamate receptors (e.g., mGlu5 receptors) following cue-induced increases in extracellular glutamate levels in the NAc core [90]. Consistent with this hypothesis, administration of the mGlu5 receptor antagonist MPEP attenuates cue-induced nicotine-seeking behavior [91]. Interestingly, systemic administration of the mGlu1 receptor antagonist EMQMCM also attenuates cue- and nicotine-induced reinstatement of nicotine seeking [92]. Due to adverse effects of AMPA and NMDA receptor antagonists in humans, attention has focused on developing type I mGlu (mGlu1) receptor antagonists for smoking cessation [36]. In addition to these mGlu1 effects, repeated nicotine exposure and subsequent withdrawal reduce mGlu2/3 receptor function in the VTA and NAc [93]. Furthermore, systemic administration of the mGlu2/3 receptor agonist LY379268 attenuates cue-induced reinstatement of nicotine seeking [93]. However, mGlu2/3 receptor agonists are nonselective and tolerance develops with repeated administration [93]. For these reasons, focus has shifted to selective positive allosteric modulators (PAMs) of mGlu2 receptors. Recent studies show that systemic administration of a PAM of mGlu2 receptors reduces nicotine- and cue-induced reinstatement of nicotine-seeking behavior, and that these effects are associated with reduced dopamine release in the NAc [94, 95]. Based on these studies, a phase II clinical trial examining the efficacy of the mGlu2 receptor PAM AZD8529 in human smokers is currently underway [96], with preliminary results forthcoming.

Acetylcholine and Nicotinic Acetylcholine Receptors

With respect to nAChR subtypes, a growing literature continues to delineate a role for α4β2* and α7* nAChRs in nicotine-seeking behavior and suggests that these two subpopulations of nAChRs may play differential roles in drug- versus cue-primed reinstatement of nicotine seeking. Indeed, varenicline, currently the best-in-class treatment for smoking cessation, was developed based on its action as a partial agonist at α4β2* nAChRs [97]. Interestingly, varenicline appears to have differential effects on the reinstatement of nicotine seeking depending upon the stimulus used to elicit drug seeking. For example, varenicline attenuates nicotine seeking following an acute priming injection of nicotine [40]. However, varenicline has no effect on cue-induced reinstatement of nicotine seeking [40] and even enhances cue-induced nicotine seeking at high doses [98]. These results suggest that α4β2* nAChRs mediate nicotine primed, but not cue-induced, reinstatement of drug seeking. This is further supported by a study showing that cue-induced reinstatement of nicotine seeking is attenuated following pretreatment with an α7*, but not α4β2*, nAChR antagonist [99]. Interestingly, chronic nicotine exposure promotes formation of α7* nAChR-NMDA receptor heterodimeric protein complexes in the hippocampus, and blocking this interaction attenuates cue-induced nicotine seeking [100]. Taken together, these findings indicate that nicotine priming-induced reinstatement of drug seeking is mediated by α4β2* nAChRs and that cue-induced reinstatement of nicotine seeking is mediated by α7* nAChRs.

The role of other nAChR subtypes in nicotine seeking is less clear. In light of varenicline’s modest efficacy in promoting long-term abstinence [11], more recent studies have focused on newer subtype-specific nAChR agonists. Systemic administration of the α7* nAChR agonist ABT-107, and the α4β2*/α6β2* agonist ABT-089 attenuates the reinstatement of nicotine seeking indicating an important role for α7* nAChRs and α4-, α6-, and β2-containing nAChRs, respectively, in this behavioral response [101]. A more recent study found that systemic administration of the α3β4* nAChR ligand AT-1001 decreases nicotine priming-induced reinstatement of drug seeking [102]. This emerging literature expands our understanding of the role of nAChR subtypes in nicotine seeking and identifies potential new targets for novel smoking cessation pharmacotherapies.

In addition to agonists of α4β2* nAChRs, PAMs of α4β2* nAChRs may also represent potential smoking cessation medications. PAMs bind nAChRs at allosteric sites that are distinct from the orthosteric binding site for nicotine. By enhancing receptor activity, as well as the probability of nicotine-induced channel opening, PAMs can substantially increase and prolong α4β2* nAChR responses to nicotine from tobacco smoke [103]. Based on this unique mechanism, PAMs of α4β2* nAChRs may reduce the amount of nicotine consumed in daily smokers and reduce the likelihood that a smoking lapse may lead to relapse. α4β2* nAChRs can assemble into two stoichiometrically and functionally different protein complexes characterized by the α4:β2 subunit ratio. The 2(α4)3(β2) and 3(α4)2(β2) subtypes represent channels with high or low sensitivity, respectively, to acetylcholine [104, 105]. Nicotine and varenicline bind to and activate both high- and low-sensitivity populations of α4β2 nAChRs [106]. While the relevance of these findings to the therapeutic effects of nicotine and varenicline is unknown, it raises the intriguing possibility that compounds targeting high- or low-sensitivity α4β2 nAChRs may be more efficacious anti-smoking medications [107]. Recently, NS9283, a PAM that binds selectively to low-sensitivity 3(α4)2(β2) nAChRs, was shown to attenuate nicotine seeking when administered systemically to rats [108]. These findings indicate that stoichiometry-selective PAMs of nAChRs, specifically 3(α4)2(β2) nAChR subtypes, may prevent smoking relapse.

Given nicotine’s demonstrated actions at endogenous nicotine acetylcholine receptors (nAChRs), activation of nAChRs has appropriately been a large focus of nicotine-mediated behavioral investigations. However, it is also apparent that altering acetylcholine levels is sufficient to alter nicotine-mediated behaviors – particularly nicotine-seeking behavior. Several studies have been performed with acetylcholinesterase inhibitors (AChEIs), which increase extracellular levels of acetylcholine in the brain and augment cholinergic transmission through inhibition of acetylcholinesterase, a catabolic enzyme responsible for metabolizing acetylcholine in the synapse [109, 110]. Systemic administration of the AChEIs galantamine [37] and donepezil [111] attenuates nicotine seeking in rats, suggesting that enhanced cholinergic tone is sufficient to reduce nicotine consumption and smoking relapse. The translational implications of these findings are supported by a small clinical trial showing a significant reduction in total daily cigarettes smoked and the subjective measures of smoking in cigarette smokers treated with galantamine [112]. Moreover, systemic galantamine administration improves cognitive performance in rodents and humans during nicotine withdrawal [113, 114]. Given that cognitive deficits during nicotine withdrawal predict smoking relapse [115, 116], these results suggest that AChEIs may improve cognitive performance in abstinent smokers and prevent smoking relapse. Taken together, these studies suggest that AChEIs could be re-purposed as pharmacotherapies for smoking cessation [117].

GABA

GABA is the canonical inhibitory neurotransmitter and an increasing number of studies are delineating GABAergic regulation of reward-related activity [60, 118, 119]. With respect to nicotine-seeking behavior, systemic administration of the GABAB receptor agonist CGP44532 has been shown to attenuate cue-induced reinstatement of nicotine-seeking behavior [120]. Consistent with these effects, the GABAB receptor agonist baclofen decreases nicotine priming-induced reinstatement of drug seeking [121]. While baclofen also reduces total cigarettes smoked per day and tobacco craving in human smokers [122], compliance is limited by adverse effects including cognitive impairments, sedation, muscle relaxation and tolerance [123]. In contrast, PAMs of GABAB receptors have fewer adverse effects than full agonists. PAMs of GABAB receptors potentiate GABA signaling only in brain regions and at times when endogenous GABA is released [124]. Systemic administration of BH177, a PAM of GABAB receptors, attenuates cue-induced reinstatement of drug seeking in rats [125]. Collectively, these findings indicate an important role for GABAB receptors in nicotine seeking and suggest that the efficacy of PAMs of GABAB receptors in smoking cessation should be explored further.

In addition to the effects of pharmacological agents of GABA receptors on nicotine seeking, recent studies have begun to examine the effects of chronic nicotine exposure and subsequent withdrawal on the endogenous GABA system. Cue-induced reinstatement of nicotine seeking is associated with increased expression of the GABAA receptor subunits α1 and γ2 in synaptic membrane fractions from the medial prefrontal cortex (mPFC) [126]. Furthermore, inhibiting surface expression of GABAA receptors in the dorsal, but not ventral, mPFC increases nicotine seeking, suggesting a region-specific role of mPFC GABAA receptors in relapse [126]. Consistent with these findings, infusions of muscimol, a GABAA receptor agonist, into the mPFC attenuates cue-induced reinstatement of nicotine seeking [126]. Thus, it has been proposed that increased GABAA receptor signaling in the mPFC may represent a compensatory response to reduce nicotine seeking [126].

Endocannabinoids

Given the critical involvement of increased mesolimbic dopamine signaling in nicotine reinforcement and behavior, preclinical studies have begun to study endocannabinoid regulation of both the dopamine system and nicotine-seeking behavior. Indeed, studies have focused on cannabinoid-1 (CB1) receptors due to their ability to regulate VTA dopamine cell firing and dopamine release in the NAc [127, 128]. In addition, systemic administration of CB1 receptor antagonists and inverse agonists attenuates the reinstatement of nicotine-seeking behavior [81, 129-132]. Consistent with these effects, activation of CB1 receptors promotes nicotine seeking during withdrawal [133]. In contrast to CB1 antagonist effects, CB2 receptor antagonists do not affect reinstatement of nicotine seeking [133]. Overall, these findings highlight a role for the endocannabinoid system, specifically CB1 receptors, in the reinstatement of nicotine seeking.

There are two endogenous ligands for the cannabinoid receptors: anandamide (AEA) and 2-arachidonoylglycerol. Pharmacological inhibition of FAAH, the primary catabolic enzyme that breaks down AEA, attenuates the reinstatement of nicotine seeking, reduces nicotine-induced excitation of VTA dopamine neurons and decreases nicotine-induced increases in extracellular dopamine levels in the NAc shell of rats [79-81]. Consistent with these effects, FAAH inhibitors also decrease nicotine reinstatement in non-human primates [134]. Inhibition of FAAH increases levels of the endocannabinoid AEA as well as the noncannabinoid fatty acid ethanolamides oleoylethanolamide (OEA) and palmitoylethanolamide (PEA) (see the section Dopamine above for a discussion of OEA and PEA in nicotine seeking) [135, 136]. The effects of FAAH inhibitors on nicotine seeking are mediated, in part, by activation of CB1 receptors [134, 137]. Consistent with these effects, systemic administration of AM404, an inhibitor of the AEA transporter, reduces nicotine-induced elevations in extracellular dopamine levels in the NAc shell and attenuates nicotine-seeking behavior, effects likely due to increased levels of AEA in the brain [138-140]. Thus, novel pharmacotherapies targeting FAAH/CB1 receptor signaling may represent promising smoking cessation medications.

Norepinephrine

In addition to nicotine and nicotine-associated cues, stress exposure can also elicit nicotine seeking during withdrawal. The effects of stress on drug seeking are mediated by numerous neurotransmitter and neuromodulator systems including norepinephrine transmission [141]. Systemic administration of the α2 adrenergic receptor agonist clonidine attenuates stress-induced reinstatement of nicotine seeking [142]. These effects are due, in part, to activation of α2 adrenergic receptors in the central nucleus of the amygdala (CeA) [143]. Systemic administration of the α1 adrenergic receptor antagonist prazosin attenuates nicotine- and cue-induced reinstatement of nicotine seeking as well as nicotine-induced release of dopamine in the NAc shell [144]. These studies suggest that α1 and α2 adrenergic receptor agonists may reduce smoking relapse in human smokers. While no studies have examined the efficacy of α1 adrenergic receptor agonists in human smokers, α2 adrenergic receptor agonists have been shown to reduce stress- and cue-induced nicotine craving in human smokers [145-147]. β-Adrenergic receptors have also been shown to play a role in nicotine seeking. For example, administration of the nonselective β-adrenergic receptor antagonist propranolol transiently reduces nicotine reinstatement [148]. Consistent with these effects, propranolol decreases nicotine craving in human smokers [149]. These exciting translational studies suggest that α2 adrenergic receptor agonists and β-adrenergic receptor antagonists could be efficacious smoking cessation medications.

Serotonin

In addition to the norepinephrine system, central serotonin signaling has also been examined in relapse models. Systemic administration of the 5-HT2A receptor antagonist M100907 attenuates nicotine seeking and these effects may be due to reduced NAc dopamine release following a priming injection of nicotine and/or re-exposure to conditioned stimuli [150]. Consistent with these effects, activation of 5-HT2A receptors is associated with increased release of dopamine in the NAc and prefrontal cortex [151-153]. While 5-HT2A receptor antagonists on their own do not affect dopamine levels, these compounds attenuate psychostimulant-induced increases in extracellular dopamine levels in the brain [154, 155]. Recent studies have also examined the efficacy of serotonin (5-HT) 2C receptor agonists in the nicotine reinstatement model. Similar to 5-HT2A receptor antagonists, 5-HT2C receptor agonists attenuate nicotine seeking in rats [150]. Thus, selective ligands of 5-HT receptor subtypes have been proposed as novel smoking cessation medications based on their ability to regulate dopamine transmission in the brain [156].

Neuropeptides

Nicotine interacts with many neuropeptide systems to promote reinforcement and reinstatement (for review see [157]). For example, dysregulation of dynorphin/kappa opioid receptor signaling in the brain may contribute to stress-induced reinstatement of drug seeking [158, 159]. A recent study showed that systemic administration of the selective kappa opioid receptor antagonist nor-binaltorphimine attenuates stress-, but not cue-, induced reinstatement of nicotine seeking [160]. Interestingly, systemic administration of the mixed mu/kappa opioid receptor antagonist naltrexone reduces cue-induced reinstatement of nicotine seeking [161]. Taken together, these results suggest that opioid receptor subtypes may play differential roles in nicotine seeking with mu opioid receptors involved in cue-induced nicotine seeking and kappa opioid receptors involved in stress-induced nicotine seeking.

Stress-induced reinstatement of nicotine seeking is also mediated by corticotropin-releasing factor 1 (CRF1) receptors. For example, intracerebroventricular infusions of the nonselective CRF1/CRF2 receptor antagonist D-Phe CRF(12–41) attenuates stress-induced reinstatement of nicotine seeking [142]. These effects appear to be due to pharmacological inhibition of CRF1 receptors as selective antagonists of CRF1, but not CRF2, receptors decrease stress-induced reinstatement of nicotine seeking [162-164].

Increased hypocretin transmission mediates the reinforcing effects of nicotine [165] and may produce a state of hyperarousal that promotes drug seeking [166]. In agreement, an infusion of hypocretin directly into the ventricles reinstates nicotine seeking [163]. Moreover, systemic administration of the hypocretin-1 receptor antagonist SB334867 reduces cue-induced nicotine seeking and these effects are due, in part, to increased protein kinase C signaling in the NAc [167]. In contrast, the role of hypocretin-2 receptors in nicotine seeking is not clear. One study found no effect of the hypocretin-2 receptor antagonist TCSOX229 on cue-induced nicotine seeking [167]. However, another study showed that systemic administration of the hypocretin-2 receptor antagonist 2-SORA attenuates cue-, but not nicotine-, induced reinstatement of drug seeking [168]. Thus, these preliminary studies suggest that hypocretin transmission may play an important role in cue-induced nicotine seeking. In addition to kappa opioid, CRF and hypocretin systems, there is emerging evidence that other neuropeptide systems may play an important role in nicotine seeking [157]. For example, systemic administration of the melanocortin 4 receptor antagonists HS014 and HS024 attenuates stress-induced reinstatement of nicotine seeking [169]. Taken together, these findings clearly identify a role for neuropeptide systems in nicotine reinstatement and suggest the neuropeptide-based therapies may prevent stress-induced nicotine seeking.

Recent studies have begun to examine the role of metabolic factors in regulating nicotine-mediated behaviors [170]. For example, glucagon-like peptide-1 (GLP-1), an incretin hormone, has been shown to regulate both food and drug reinforcement [171]. With regard to nicotine addiction, systemic administration of a GLP-1 receptor agonist attenuates nicotine-induced increases in extracellular dopamine levels in the NAc and reduces the rewarding properties of nicotine [172]. GLP-1 receptor agonists also reduce nicotine self-administration indicating that activation of GLP-1 receptors is sufficient to reduce the reinforcing efficacy of nicotine [173]. The role of GLP-1 signaling in nicotine seeking, however, is unclear. From a translational perspective, it will be important to determine the efficacy of GLP-1 receptor agonists in reducing nicotine withdrawal-mediated behaviors including the reinstatement of nicotine seeking to support clinical trials of GLP-1 receptor agonists in human smokers.

As noted in the section Neurotransmitter Mechanisms Regulating Nicotine Seeking above, nAChRs in the mesoaccumbens dopamine system are known to play a critical role in nicotine-taking and -seeking behaviors [57, 58, 174, 175]. Activation of nAChRs in other brain regions such as the amygdala, hippocampus, and PFC are also known to impact nicotine taking, particularly in the context of reward learning and cognition [176, 177, as reviewed in,178]. Over the last 20 years, seminal studies from different laboratories have revealed important insights into the nAChR mechanisms underlying nicotine-induced plasticity. Early electrophysiology studies focused on nicotine-mediated synaptic plasticity in the hippocampus and in the VTA [43, 45, 179-182]. In subsequent years, electrochemical investigations also revealed plasticity-related mechanisms through which nicotine enhances phasic dopamine signaling within the NAc [46, 47, 183]. In many of these investigations, the authors often suggested that nicotine-induced plasticity in specific brain regions could mediate nicotine reinforcement, nicotine-mediated reward learning, and nicotine-seeking behavior. Many of the electrophysiological and electrochemical investigations have been performed using acute, single nicotine exposure to provide key insights into the mechanisms underlying these phenomena. Of particular note, the use of in vitro slice application of nicotine doses that mimic nicotine exposure levels in plasma of human smokers has facilitated significant advancements in our understanding of nAChR plasticity [184]. Increasingly, these in vitro investigations have begun to use repeated nicotine exposure, a model that more closely mirrors repeated exposure in human smokers, especially with respect to the mechanisms underlying nicotine withdrawal-induced behavioral deficits [185, 186]. Indeed, the mechanisms underlying nicotine-mediated plasticity may differ from those mediating acute nicotine effects. In this section, we will review key findings on nicotine-mediated plasticity and discuss the implications of such findings on our understanding of nicotine-seeking behavior and smoking relapse. We will also highlight areas where additional study can provide greater understanding of these neurobiological mechanisms and can potentially provide new insights for novel therapeutic interventions.

Ventral Tegmental Area

As noted above, VTA nAChRs are necessary and sufficient for nicotine reinforcement, as measured by nicotine self-administration in rodents [58, 175, 187, 188]. Thus, several slice electrophysiological studies have examined the mechanisms through which VTA nAChRs mediate neuronal activity and signaling in the mesolimbic dopamine system. Dopamine neurons in the VTA exhibit two types of firing patterns distinguished as tonic (3–7 Hz) or burst (15–20 Hz) firing [189-191]. Burst firing of VTA dopamine neurons in particular, is known to play a critical role in drug-taking and drug-seeking behaviors [192-194]. Previous work revealed that even in the absence of nicotine, β2* nAChRs are required for dopamine burst firing, whereas spontaneous burst firing is still observed in mutant mice lacking α7 nAChRs [57]. The presence of nicotine has been shown to enhance burst firing of VTA dopamine neurons [57, 195, 196], an effect that is absent in mutant mice that do not express the β2 nAChR subunit [57]. The role of α7 nAChRs in nicotine-induced burst firing, however, appears to be more complex. While there are no overall differences in nicotine-induced burst firing of VTA dopamine neurons between α7 nAChR knockout mice and wild-type controls, the emergence of both inhibitory (in ½ of tested neurons) and enhanced (in ½ of tested neurons) dopamine responses to nicotine are seen in α7 nAChR knock-out mice [57]. Therefore, it has been proposed that β2* nAChRs play a role in regulating dopamine neuronal excitation, while α7* nAChRs play a role in fine-tuning dopamine neuronal responses [57]. However, important questions regarding the role of nAChR subtype-specific regulation of VTA dopamine cell firing in nicotine-seeking behavior remains to be tested.

In addition to activation of nAChRs, nicotine exposure causes desensitization of nAChRs, which may in part explain acute tolerance to nicotine [197, 198]. Notably, α7* and β2* nAChRs desensitize at different rates [184]. Specifically, acute nicotine exposure in slice, at concentrations thought to persist in the brain hours after cigarette smoking (20–80 nM) enhances VTA dopamine burst firing by preferentially desensitizing β2* nAChRs on GABAergic interneurons, and not affecting (or limited desensitization of) presynaptic α7* nAChRs on glutamatergic afferents [43, 182, 184, 199]. This differential desensitization of nAChRs results in decreased GABAergic inhibition of dopamine neurons and increased glutamatergic drive onto dopamine neurons, resulting in increased VTA dopamine neuron firing. A relatively recent study demonstrated that β2* nAChRs on GABAergic interneurons are required for intracranial nicotine self-administration [200]. The role of desensitization of these specific receptors in nicotine seeking remains to be tested. A more recent body of work has demonstrated that α6* nAChRs on VTA neurons are more resistant to desensitization, allowing for prolonged dopamine cell depolarization by nicotine [44]. However, the role of α6* nAChRs is complicated by evidence that this receptor population is also expressed on GABAergic afferents in apposition to VTA dopamine neurons [199]. Further understanding of the precise role of nAChR subtypes and the desensitization kinetics of these receptor subpopulations in response to acute and chronic nicotine exposure in nicotine-seeking behavior is still needed.

It is important to note that the concentrations of nicotine used in many of the slice electrophysiology experiments described above were selected because they fall within the range typically found in the plasma of human smokers (50–500 nM) [184, 201]. We also note that the concentrations of plasma nicotine in a human smoker are likely much higher than nicotine concentrations in the brain [22, 201-203]. For example, the concentration of nicotine in the rodent brain is approximately 0.3% of the plasma nicotine levels measured in rats following nicotine self-administration [22]. Thus, it is possible that the nicotine concentrations used in some slice experiments are higher than would be identified in brain tissue of human smokers and of rodents self-administering nicotine. Due the potential nicotine dose-related issues indicated above, an ongoing consideration for the field is to identify mechanistic insights from nicotine electrophysiological studies in VTA slices and translate them to nicotine-related behavior. Electrophysiological investigations in rodents that have undergone abstinence after nicotine self-administration, and re-exposure to nicotine and nicotine-related cues, are needed to understand the role of region-specific nAChR activation and desensitization in nicotine seeking.

Electrophysiological experiments in which an animal is first exposed to acute or repeated nicotine can offer unique insights into the consequences of such exposure on both synaptic plasticity and nicotine-related behavior. Both acute and chronic nicotine administration can alter nAChR expression profiles in the VTA. However, the chronicity and route of administration, as well as dose, likely have differential impacts on neuroadaptations, as these factors drastically impact nicotine-seeking behaviors. Broadly, nAChRs are upregulated in the VTA following chronic and self-administered nicotine in rats [204-206]. The nAChR upregulation observed in human smokers is long lasting, even during smoking abstinence [207] and is thought to be a compensatory change in response to the nAChR desensitization described above. Incubation of nicotine in cultured VTA cells results in the upregulation of α4β2* nAChRs [208]. Likewise, chronic subcutaneous nicotine exposure in rats increases α4β2* and α7* nAChR binding sites in the VTA [209]. Nicotine-mediated upregulation of nAChRs is likely to influence behavior, as functional upregulation of α4* nAChRs in VTA GABAergic neurons has been shown to increase sensitivity to nicotine reward, measured by conditioned place preference [210]. While upregulation of nAChRs impacts reward-related behaviors, the role of nAChR upregulation on nicotine seeking is not well studied. It has been proposed that persistent upregulation of nAChRs during nicotine abstinence may promote craving, resulting in relapse [205]. However, additional work is needed to more fully test this hypothesis.

In addition to altering nAChR expression, nicotine can also alter glutamate receptor profiles in the VTA, thereby impacting synaptic strength. For instance, an acute nicotine injection followed by a period of abstinence increases the AMPA/NMDA ratio in VTA dopamine neurons [45]. More specifically, nicotine application in brain slices increases AMPA/NMDA ratio, which occurs via α7* but not α4β2* nAChR mechanisms [199]. Extensions of this published work evaluating AMPA/NMDA ratio in VTA slice from rats following self-administration of nicotine, and during abstinence following self-administration, will provide further understanding of the impact of glutamatergic synaptic plasticity on nicotine-seeking behaviors. Indeed, increased synaptic strength, via altered nAChR and glutamate receptor-mediated plasticity, may contribute to both the maintenance of nicotine-taking behavior and to nicotine-seeking behavior.

Nucleus Accumbens

The NAc receives direct dopaminergic projections from the VTA. Many of the VTA nAChR mechanisms noted in the previous section also regulate NAc dopamine signaling, which is known to play a critical role in reward-related behavior. However, the role of NAc nAChRs in mediating nicotine reinforcement was initially unclear, given that blockade of NAc nAChRs failed to produce an attenuation of nicotine self-administration [183]. However, more recent work has revealed complex effects of nicotine and NAc nAChRs on dopamine signaling, which provides some clarity for the previously observed lack of NAc nAChR effects on nicotine self-administration. The current evidence suggests that nicotine modulates dopamine release in the NAc, and in the dorsal striatum, in a frequency-dependent manner via accumbal nAChR desensitization [46, 47]. Specifically, nicotine decreases dopamine release evoked by tonic-like firing activity, but maintains, and in some instances increases, dopamine release during phasic-like frequency stimulation – thereby acting as a frequency filter for dopamine release [46, 47, 211, 212]. This frequency gating is dependent on presynaptic β2* [47], α6* [213-215], α4* [214], and β3* nAChRs [216, 217]. Mechanistically, it has been proposed that this frequency filtering of tonic and phasic mediated dopamine release could underlie the encoding of salient, nicotine-associated stimuli [46, 47]. This has important behavioral implications, given the impact of both nicotine-paired cues and the encoding of such cues in guiding reward- or drug-seeking behavior [47, 218]. However, whether this nicotine-mediated frequency filtering directly contributes to cue-induced reinstatement remains untested.

Approximately 50% of nAChRs expressed on dopamine terminals in the striatum are of the α6α4β3β2* subtype [219]. Evidence suggests that the α6* nAChR is important for striatal dopamine release and nicotine-related behaviors [220, 221]. Indeed, intra-NAc shell infusion of α-conotoxin-MII, an α6* nAChR antagonist, reduced motivation to self-administer intravenous nicotine infusions in combination with associated cues [222]. To our knowledge, further parsing of whether α6* nAChRs mediate nicotine seeking has not been conducted, and this presents an interesting opportunity for future work. In addition to the effects of direct nicotine exposure, withdrawal from nicotine delivered via drinking water has been shown to increase basal dopamine concentrations in the NAc shell and to decrease phasic and tonic dopamine release, but with increased contrast between tonic and phasic release [223]. This change was accompanied by decreased control of β2* nAChRs over dopamine release in the NAc, as inhibition of β2* nAChRs was ineffective in attenuating phasic dopamine release in mice withdrawn from nicotine exposure [223]. Extending these studies to investigations of accumbal dopamine release during nicotine abstinence or withdrawal and subsequent cued reinstatement would provide further understanding of the role of nAChR subtypes in the mechanisms by which conditioned cues facilitate relapse.

In addition to the aforementioned effects of nicotine on NAc dopamine levels, nicotine also increases extracellular glutamate levels in the NAc [224, 225]. Nicotine-induced glutamate release can occur independently of dopamine-related mechanisms, as dopamine receptor antagonism in the NAc and denervation of dopamine efferents to the NAc had no effect on glutamate release stimulated by nicotine [225]. More recent work has shown that glutamate release in the NAc sensitizes over repeated nicotine exposures when delivered intravenously [226]. Additionally, chronic nicotine injections, at doses that result in locomotor sensitization, have been shown to increase dendritic length and spine density in the NAc shell [227], which could contribute to changes in glutamate release. These changes in dendrites and spines may underlie long-lasting behavioral sensitization to chronic nicotine exposure and could be important for nicotine-seeking behaviors. Nicotine has also been shown to regulate glutamate receptor expression. Nicotine self-administration may result in increased NR2B NMDA subunit expression in NAc shell, although these changes did not reach significance [228]. In contrast, nicotine exposure has been shown to downregulate NR2B-containing NMDA subunits on nAChR-expressing dopaminergic terminals in NAc synaptosomes [229]. Moreover, nicotine self-administration is associated with decreased mGlu2/3 receptor expression in the NAc shell [93]. Additional changes in the cysteine/glutamate exchange and glial glutamate exchange systems, important regulators of glutamate release, have also been observed after nicotine exposure [84, 86, 88]. For instance, acute activation of the cystine/glutamate exchange (xCT) system with N-acetylcysteine attenuates cue-induced nicotine reinstatement [87], effects that are mediated by mGluR 2/3 [88], although results describing the effective dose of N-acetylcysteine to suppress reinstatement are mixed. Importantly, N-acetylcysteine has been shown to reduce daily cigarettes smoked in smokers [86], especially if combined with varenicline [89]. Work in human smokers testing the efficacy of N-acetylcysteine on relapse and smoking cue-related tasks is warranted. Withdrawal from nicotine self-administration also reduces expression of xCT and glutamate transporter-1 in the NAc [86]. Interestingly, reductions of xCT are not observed during withdrawal if chronic nicotine is delivered via minipump. This could indicate that nicotine-induced reduction in xCT requires phasic daily nicotine exposure, as opposed to constant nicotine exposure [86]. However, it is also possible that the xCT reduction may act as an interoceptive cue predicting the availability of nicotine. This remains to be tested.

The above nicotine-induced changes in glutamate receptor expression are consistent with the glutamate hypothesis of addiction, that drug-induced alterations in glutamate homeostasis to the NAc are critical in controlling drug-seeking behavior [62]. One body of work in particular has demonstrated that reinstatement of nicotine seeking is mediated by glutamatergic plasticity in the NAc core [84]. This work specifically demonstrated that a cue-induced reinstatement test increased extracellular glutamate, spine head diameter, and AMPA/NMDA ratio in the NAc. Withdrawal from nicotine self-administration resulted in increased expression of NR2A and NR2B subunit protein expression in the NAc core, while pharmacological inhibition of these subunits attenuated cue-induced reinstatement. These results suggest that rapid glutamatergic plasticity in the accumbens contributes to nicotine-seeking behavior elicited by re-exposure to conditioned cues previously paired with nicotine taking.

Hippocampus

One facilitator of relapse is that a drug-paired context or cue serves as a memory for the drug itself and promotes drug-seeking behavior. Therefore, nicotine-induced plasticity in regions that regulate memory consolidation and learning may also mediate nicotine-seeking behavior. Nicotine has been shown to both improve working memory and to enhance hippocampal-dependent learning [230]. In contrast, chronic nicotine administration, when delivered at high doses, enhances hippocampal neurogenesis, the growth of new neurons, specifically in the dentate gyrus region of the hippocampus [231-233]. Hippocampal neurogenesis has been observed after daily 21-h long-access sessions, but not daily 1-h short-access sessions, of nicotine self-administration [234]. In contrast, short access to nicotine self-administration has been reported to increase cell death and decrease neurogenesis in the dentate gyrus [235]. However, the relationship between changes in neurogenesis and nicotine-seeking behavior and cognition are not known. As hippocampal neurogenesis is suggested to play a role in learning and memory [236], one hypothesis is that nicotine-induced increases in neurogenesis may facilitate learned associations between nicotine and paired environmental cues, and thus facilitate cue-induced nicotine seeking during abstinence.

Nicotine induces hippocampal long-term potentiation (LTP) in vitro and in vivo, which is thought to be a neurophysiological correlate of learning and memory [237]. Specifically, acute and chronic nicotine exposure produces LTP in the CA1 [238] and dentate gyrus [239] regions of the hippocampus. In addition, in vitro activation of nAChRs, using local acetylcholine application, potentiates excitatory activity via presynaptic and postsynaptic nAChR mechanisms in hippocampal slices [240]. Systemic experimenter-administered nicotine is also sufficient to increase synaptic LTP in the dentate gyrus [241]. This systemic nicotine-induced LTP can be blocked by dopamine D1-receptor blockade, indicating that nicotine-induced hippocampal plasticity requires dopaminergic signaling [241]. This mechanism may be important for nicotine seeking, as dopamine D1 receptor blockade also blocks nicotine-conditioned place preference, which is dependent on nicotine-paired context and/or cues [241]. In the hippocampus, nAChRs are densely expressed on inhibitory interneurons [242], and nicotine-induced hippocampal LTP is at least in part dependent on local disinhibition of granule cells [243]. Nicotine-mediated hippocampal plasticity and its role in learning and plasticity have been discussed extensively [230, 244, 245].

Amygdala

The amygdala is associated with drug taking, drug reward, and relapse. While not as extensively studied as the hippocampus, the amygdala also plays an important role in the neurocircuitry mediating nicotine-taking and -seeking behaviors [246]. Like other brain regions discussed, nicotine induces synaptic plasticity in the amygdala. Chronic nicotine administered via drinking water in mice facilitates LTP in the amygdala, a process that depends on activation of α7* and β2* nAChRs [247]. Further, nicotine-induced LTP in the amygdala is long-lasting, up to 72 h following nicotine cessation. Given that these changes remain following cessation of nicotine exposure, it is possible that they are important in mediating nicotine-seeking behavior during abstinence, although this has not been tested. Recent work has also established the basolateral amygdala (BLA) and central amygdala (CeA) as important subregions mediating nicotine seeking and craving. Stress-induced reinstatement of nicotine-seeking behavior is attenuated by activation of α2 adrenergic receptors in the CeA [143]. Similarly, blockade of dopamine D3 receptors in the BLA attenuates cue-induced reinstatement of nicotine seeking [248]. These findings suggest that CeA α2 adrenergic receptors and BLA dopamine D3 receptors differentially mediate reinstatement of nicotine seeking elicited by stress and cues. Further, inhibition of nicotine-associated neuronal ensembles, using Daun02 in the BLA [249] and CeA [250], reduced drug-seeking behavior, indicating the importance of these regions in nicotine seeking, and perhaps in nicotine craving. Future research on these neuronal circuits will provide more insights into the role of the amygdala in nicotine-seeking behaviors.

Prefrontal Cortex

The prefrontal cortex (PFC) is known to mediate drug reinforcement, extinction learning, and drug-seeking behavior. In the PFC, plasticity depends on correlative activity at pre- and postsynaptic sites, referred to as spike-timing-dependent plasticity [251, 252]. Nicotine increases the threshold for this spike-timing-dependent plasticity in medial PFC [253], while also increasing glutamatergic drive to these same regions via activation of presynaptic nAChRs [254, 255]. Both β2* and α7* nAChRs appear to be important in modulating glutamate release, as measured using PFC synaptosomes, though via different mechanisms [256]. PFC β2* nAChRs regulate glutamate release through voltage-gated calcium channels, whereas α7* nAChRs regulate glutamate release through intracellular calcium stores [256]. Chronic noncontingent nicotine administration results in the upregulation of β2* and downregulation of GluA1 and GluA2/3 in the PFC [257]. Likewise, chronic nicotine enhances NMDA currents in PFC [258]. Investigating the impact of self-administered nicotine, and its abstinence, on glutamate and nicotinic receptor expression in the PFC is an important next step to these experiments, as important differences have been noted between contingent (i.e., self-administration) and noncontingent procedures [28, 259]. Little attention has focused on the effects of withdrawal and abstinence from nicotine on plasticity or receptor function in the PFC and this should be a focus of future research questions to better understand the mechanisms underlying nicotine seeking.

An ongoing challenge for the nicotine and tobacco fields is the need to identify and develop novel, efficacious smoking cessation pharmacotherapies, especially given the modest efficacy of current tobacco cessation methods and the high rates of smoking relapse. As we have emphasized throughout this review, the identification of novel therapeutic targets can be strongly informed and guided by preclinical investigations in rodent models of nicotine addiction, including the reinstatement model of smoking relapse. Indeed, much of our understanding of the dopaminergic, glutamatergic, and cholinergic mechanisms underlying nicotine seeking and relapse behavior has been delineated from research in rodent models [67, 71, 87, 91, 92, 102]. Mechanistically, different neurotransmitter systems also interact to influence nicotine-seeking behavior and smoking relapse. As we have described, previous studies have already examined cholinergic and endocannabinoid influences on the dopamine system and how such processes mediate relapse behavior [46, 47, 128, 129, 132]. In many of the preclinical studies to date, investigators have demonstrated the efficacy of regulating extracellular neurotransmitter levels or manipulating specific neurotransmitter receptors with pharmacological antagonists or agonists (both full and partial agonists) to alter cue and/ or nicotine-primed reinstatement of drug seeking in rodents. More recently, preclinical studies have begun to screen the efficacy of PAMs of nAChRs in attenuating nicotine seeking [108]. By enhancing endogenous tone of neurotransmitter levels in the brain, PAMs may have greater efficacy than full and partial agonists in reducing nicotine seeking and produce less adverse effects. PAMs of α4β2* nAChRs and GABAB receptors have recently been shown to attenuate nicotine reinstatement, results that support pharmacological approaches towards increasing endogenous acetylcholine and GABA tone, respectively, at these receptor populations during smoking cessation [108, 125]. Moreover, as the role of specific nAChR subtypes in nicotine seeking becomes clearer, stoichiometry-selective compounds targeting specific populations of nAChRs may represent efficacious smoking cessation therapies. Consistent with this strategy, a recent study showed that a PAM of nAChRs containing three α4 subunits and two β2 subunits reduces nicotine seeking in rats [108]. From a translational perspective, these preclinical studies identify novel pharmacological approaches that attenuate nicotine-seeking behavior in rodent models, and may also be used to decrease relapse behavior in human smokers.

In addition to cue- and nicotine-induced reinstatement studies, and their therapeutic implications for smoking relapse, the field will greatly benefit from additional investigations of neurotransmitter mechanisms underlying stress-mediated relapse behavior. Preclinical studies thus far revealed important roles for the norepinephrine, endocannabinoid, and neuropeptide systems (including opiate receptor and CRF mechanisms) in stress-primed reinstatement [142, 150, 160, 260]. Another critical consideration for ongoing research will be a closer examination of gender differences and their influence on stress-mediated relapse. Indeed, emerging data from multiple studies continue to provide evidence for gender-specific differences in successful quit attempts in smokers [19] as well as sex-specific effects regarding the role of stress in nicotine use and relapse in preclinical models and in humans [261-263]. Evidence from smokers suggests that men are more sensitive to the pharmacological effects of nicotine, where women are more sensitive to smoking-related cues [264, 265], and these gender differences have important implications for smoking relapse and cessation strategies [266]. It is intriguing to think that sex-specific mechanisms underlying stress-mediated relapse and cue reactivity may be differentially targeted by novel smoking cessation pharmacotherapies to reduce relapse in male and female smokers.

In addition to these behavioral studies, significant mechanistic insight has been gained through in vitro investigations of the neuroadaptations associated with nicotine exposure. These observed neuroadaptations include nicotine-mediated upregulation of subtype-specific nAChRs [204-206], nicotine-induced synaptic plasticity [43, 181, 239, 247], nicotine-mediated frequency filtering of dopamine signaling [46, 47], nicotine-induced alterations in NAc dendritic spine length and density [227], and nicotine-mediated hippocampal neurogenesis [231-233]. The behavioral implications of these findings are often interpreted based on the brain regions in which they are identified. Specifically, nicotine-mediated neuroadaptations in specific loci are thought to play a role in nicotine reinforcement (VTA and NAc), nicotine-related learning (PFC and hippocampus), nicotine craving (VTA, NAc, amygdala, and PFC), and cue-mediated nicotine-taking and nicotine-seeking behaviors (NAc, hippocampus, and amygdala). A critical factor in these mechanistic studies is a consideration of whether the in vitro experiments were performed using behaviorally relevant nicotine doses. Admittedly, it is challenging to translate relevant nicotine doses from a behavioral in vivo experiment to physiologically relevant nicotine doses in an in vitro slice experiment. In particular, we note that nicotine concentrations used in some in vitro slice experiments may be higher than would be observed in the brain of a rodent self-administering nicotine. In some previous in vitro slices studies, lower nicotine concentrations (20–80 nM) have also been used as an estimate of nicotine concentrations that may exist in the brains of human smokers hours after cigarette smoking [184]. We note that the challenges associated with in vitro nicotine dose will continue to be an important consideration for future studies. As in vitro studies continue to be performed, we also argue that an effective approach for gaining more direct mechanistic insight into nicotine seeking will be the examination of nicotine-induced neuroadaptations in rodents, or in rodent brain slices, after nicotine self-administration and subsequent abstinence. Similarly, important insights can be gained from performing in vitro slice studies in tissue following stress-, drug-, and cue-primed reinstatement of nicotine seeking. Unfortunately, there is a paucity of literature investigating synaptic plasticity that occurs during the reinstatement of nicotine seeking. Clearly, these experiments are not trivial. Thus, such approaches will benefit from, and likely require, collaborations between in vivo- and in vitro- focused nicotine researchers. This presents an exciting opportunity for the nicotine and tobacco field that has the potential to greatly enhance our understanding of nicotine seeking and craving-induced relapse behavior.

Here, we have presented both in vivo and in vitro preclinical investigations and their importance for guiding and informing clinical research aimed at providing improved pharmacotherapies to prevent nicotine relapse. However, one challenge in translating preclinical findings to clinical investigations is the possibility that individual differences in subpopulations of tobacco users might lead to differential neuroadaptations, and therefore differential efficacy of smoking cessation pharmacotherapies [266, 267]. Therefore, these are aspects that must also be considered in the experimental design of preclinical investigations, to better inform clinical investigation (e.g., how might age or sex moderate reinstatement due to stress, drug, or environmental cues).

Another highly relevant consideration is the changing landscape of tobacco use. While rates of smoking traditional cigarettes continue to decline, use of noncombustible products (electronic cigarettes; snus) is increasing [268]. Thus, one remaining question is whether subpopulations of tobacco product users have different neurophysiological mechanisms driving nicotine seeking. Thus, researchers should keep the tobacco product population, modeled in their studies, in mind. This could provide important information for cessation treatment across populations of tobacco users.

Developing the next generation of smoking cessation medications depends on advancing our understanding of the neurobiological and neurophysiological mechanisms underlying nicotine seeking and smoking relapse. Here, we have highlighted important strategies that could be used to develop novel smoking cessation medications. Identifying more efficacious pharmacotherapies to treat smoking relapse are needed to further decrease tobacco-related morbidity and mortality.

L.E.R. and N.A.A. were supported by the Yale Tobacco Center of Regulatory Science (TCORS) grant P50 DA036151 from the National Institute on Drug Abuse (NIDA) and the Federal Drug Administration (FDA) Center for Tobacco Products (CTP). H.D.S. was supported by grants DA037897 and DA039393 from the NIDA. The content is solely the responsibility of the authors and does not necessarily represent the official view of the NIH or the FDA.

The authors do not have any conflicts of interest to declare.

1.
Arrazola
RA
,
Singh
T
,
Corey
CG
,
Husten
CG
,
Neff
LJ
,
Apelberg
BJ
, et al.;
Centers for Disease Control and Prevention (CDC)
.
Tobacco use among middle and high school students - United States, 2011-2014
.
MMWR Morb Mortal Wkly Rep
.
2015
Apr
;
64
(
14
):
381
5
.
[PubMed]
1545-861X
2.
CDCP
.
C.f.D.C.a.P.-. Current Cigarette Smoking Among Adults - United States, 2005-2014
.
Morbidity and Mortality Weekly Report
.
2015
;
64
(
44
):
1244
40
.
3.
CDC
.
Preventing Tobacco Use Among Youth and Young Adults: A Report of the Surgeon General.
2012
, U.S. Department of Health and Human Services, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health: Atlanta, GA.
4.
Jha
P
,
Ramasundarahettige
C
,
Landsman
V
,
Rostron
B
,
Thun
M
,
Anderson
RN
, et al.
21st-century hazards of smoking and benefits of cessation in the United States
.
N Engl J Med
.
2013
Jan
;
368
(
4
):
341
50
.
[PubMed]
0028-4793
5.
Xu
X
,
Bishop
EE
,
Kennedy
SM
,
Simpson
SA
,
Pechacek
TF
.
Annual healthcare spending attributable to cigarette smoking: an update
.
Am J Prev Med
.
2015
Mar
;
48
(
3
):
326
33
.
[PubMed]
0749-3797
6.
Taylor
DH
 Jr
,
Hasselblad
V
,
Henley
SJ
,
Thun
MJ
,
Sloan
FA
.
Benefits of smoking cessation for longevity
.
Am J Public Health
.
2002
Jun
;
92
(
6
):
990
6
.
[PubMed]
0090-0036
7.
Benowitz
NL
.
Nicotine addiction
.
N Engl J Med
.
2010
Jun
;
362
(
24
):
2295
303
.
[PubMed]
0028-4793
8.
Garvey
AJ
,
Bliss
RE
,
Hitchcock
JL
,
Heinold
JW
,
Rosner
B
.
Predictors of smoking relapse among self-quitters: a report from the Normative Aging Study
.
Addict Behav
.
1992
;
17
(
4
):
367
77
.
[PubMed]
0306-4603
9.
Hughes
JR
.
Tobacco withdrawal in self-quitters
.
J Consult Clin Psychol
.
1992
Oct
;
60
(
5
):
689
97
.
[PubMed]
0022-006X
10.
Cahill
K
,
Stevens
S
,
Lancaster
T
.
Pharmacological treatments for smoking cessation
.
JAMA
.
2014
Jan
;
311
(
2
):
193
4
.
[PubMed]
0098-7484
11.
Lerman
C
,
LeSage
MG
,
Perkins
KA
,
O’Malley
SS
,
Siegel
SJ
,
Benowitz
NL
, et al.
Translational research in medication development for nicotine dependence
.
Nat Rev Drug Discov
.
2007
Sep
;
6
(
9
):
746
62
.
[PubMed]
1474-1776
12.
Le Foll
B
,
Pushparaj
A
,
Pryslawsky
Y
,
Forget
B
,
Vemuri
K
,
Makriyannis
A
, et al.
Translational strategies for therapeutic development in nicotine addiction: rethinking the conventional bench to bedside approach
.
Prog Neuropsychopharmacol Biol Psychiatry
.
2014
Jul
;
52
:
86
93
.
[PubMed]
0278-5846
13.
Henningfield
JE
,
Heishman
SJ
.
The addictive role of nicotine in tobacco use
.
Psychopharmacology (Berl)
.
1995
Jan
;
117
(
1
):
11
3
.
[PubMed]
0033-3158
14.
Stolerman
IP
,
Jarvis
MJ
.
The scientific case that nicotine is addictive
.
Psychopharmacology (Berl)
.
1995
Jan
;
117
(
1
):
2
10
.
[PubMed]
0033-3158
15.
Etter
JF
,
Eissenberg
T
.
Dependence levels in users of electronic cigarettes, nicotine gums and tobacco cigarettes
.
Drug Alcohol Depend
.
2015
Feb
;
147
:
68
75
.
[PubMed]
0376-8716
16.
Boyle
RG
,
Jensen
J
,
Hatsukami
DK
,
Severson
HH
.
Measuring dependence in smokeless tobacco users
.
Addict Behav
.
1995
Jul-Aug
;
20
(
4
):
443
50
.
[PubMed]
0306-4603
17.
Fagerström
K
,
Eissenberg
T
.
Dependence on tobacco and nicotine products: a case for product-specific assessment
.
Nicotine Tob Res
.
2012
Nov
;
14
(
11
):
1382
90
.
[PubMed]
1462-2203
18.
Hall
BJ
,
Wells
C
,
Allenby
C
,
Lin
MY
,
Hao
I
,
Marshall
L
, et al.
Differential effects of non-nicotine tobacco constituent compounds on nicotine self-administration in rats
.
Pharmacol Biochem Behav
.
2014
May
;
120
:
103
8
.
[PubMed]
0091-3057
19.
Smith
TT
,
Schaff
MB
,
Rupprecht
LE
,
Schassburger
RL
,
Buffalari
DM
,
Murphy
SE
, et al.
Effects of MAO inhibition and a combination of minor alkaloids, β-carbolines, and acetaldehyde on nicotine self-administration in adult male rats
.
Drug Alcohol Depend
.
2015
Oct
;
155
:
243
52
.
[PubMed]
0376-8716
20.
Caine
SB
,
Collins
GT
,
Thomsen
M
,
Wright
C
,
Lanier
RK
,
Mello
NK
.
Nicotine-like behavioral effects of the minor tobacco alkaloids nornicotine, anabasine, and anatabine in male rodents
.
Exp Clin Psychopharmacol
.
2014
Feb
;
22
(
1
):
9
22
.
[PubMed]
1064-1297
21.
Arnold
MM
,
Loughlin
SE
,
Belluzzi
JD
,
Leslie
FM
.
Reinforcing and neural activating effects of norharmane, a non-nicotine tobacco constituent, alone and in combination with nicotine
.
Neuropharmacology
.
2014
Oct
;
85
:
293
304
.
[PubMed]
0028-3908
22.
Smith
TT
,
Rupprecht
LE
,
Cwalina
SN
,
Onimus
MJ
,
Murphy
SE
,
Donny
EC
, et al.
Effects of Monoamine Oxidase Inhibition on the Reinforcing Properties of Low-Dose Nicotine
.
Neuropsychopharmacology
.
2016
Aug
;
41
(
9
):
2335
43
.
[PubMed]
0893-133X
23.
Harris
AC
,
Mattson
C
,
Lesage
MG
,
Keyler
DE
,
Pentel
PR
.
Comparison of the behavioral effects of cigarette smoke and pure nicotine in rats
.
Pharmacol Biochem Behav
.
2010
Aug
;
96
(
2
):
217
27
.
[PubMed]
0091-3057
24.
Goodwin
AK
,
Hiranita
T
,
Paule
MG
.
The Reinforcing Effects of Nicotine in Humans and Nonhuman Primates: A Review of Intravenous Self-Administration Evidence and Future Directions for Research
.
Nicotine Tob Res
.
2015
Nov
;
17
(
11
):
1297
310
.
[PubMed]
1462-2203
25.
O’Dell
LE
,
Khroyan
TV
.
Rodent models of nicotine reward: what do they tell us about tobacco abuse in humans?
Pharmacol Biochem Behav
.
2009
Feb
;
91
(
4
):
481
8
.
[PubMed]
0091-3057
26.
Tuesta
LM
,
Fowler
CD
,
Kenny
PJ
.
Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior
.
Biochem Pharmacol
.
2011
Oct
;
82
(
8
):
984
95
.
[PubMed]
0006-2952
27.
Rose
JE
,
Corrigall
WA
.
Nicotine self-administration in animals and humans: similarities and differences
.
Psychopharmacology (Berl)
.
1997
Mar
;
130
(
1
):
28
40
.
[PubMed]
0033-3158
28.
Rupprecht
LE
,
Smith
TT
,
Schassburger
RL
,
Buffalari
DM
,
Sved
AF
,
Donny
EC
.
Behavioral mechanisms underlying nicotine reinforcement
.
Curr Top Behav Neurosci
.
2015
;
24
:
19
53
.
[PubMed]
1866-3370
29.
Gourlay
SG
,
Benowitz
NL
.
Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine
.
Clin Pharmacol Ther
.
1997
Oct
;
62
(
4
):
453
63
.
[PubMed]
0009-9236
30.
Shoaib
M
,
Stolerman
IP
.
Plasma nicotine and cotinine levels following intravenous nicotine self-administration in rats
.
Psychopharmacology (Berl)
.
1999
Apr
;
143
(
3
):
318
21
.
[PubMed]
0033-3158
31.
Coen
KM
,
Adamson
KL
,
Corrigall
WA
.
Medication-related pharmacological manipulations of nicotine self-administration in the rat maintained on fixed- and progressive-ratio schedules of reinforcement
.
Psychopharmacology (Berl)
.
2009
Jan
;
201
(
4
):
557
68
.
[PubMed]
0033-3158
32.
Rauhut
AS
,
Neugebauer
N
,
Dwoskin
LP
,
Bardo
MT
.
Effect of bupropion on nicotine self-administration in rats
.
Psychopharmacology (Berl)
.
2003
Aug
;
169
(
1
):
1
9
.
[PubMed]
0033-3158
33.
George
O
,
Lloyd
A
,
Carroll
FI
,
Damaj
MI
,
Koob
GF
.
Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration
.
Psychopharmacology (Berl)
.
2011
Feb
;
213
(
4
):
715
22
.
[PubMed]
0033-3158
34.
Shaham
Y
,
Shalev
U
,
Lu
L
,
de Wit
H
,
Stewart
J
.
The reinstatement model of drug relapse: history, methodology and major findings
.
Psychopharmacology (Berl)
.
2003
Jul
;
168
(
1-2
):
3
20
.
[PubMed]
0033-3158
35.
de Wit
H
,
Stewart
J
.
Reinstatement of cocaine-reinforced responding in the rat
.
Psychopharmacology (Berl)
.
1981
;
75
(
2
):
134
43
.
[PubMed]
0033-3158
36.
Stoker
AK
,
Markou
A
.
Neurobiological Bases of Cue- and Nicotine-induced Reinstatement of Nicotine Seeking: Implications for the Development of Smoking Cessation Medications
.
Curr Top Behav Neurosci
.
2015
;
24
:
125
54
.
[PubMed]
1866-3370
37.
Hopkins
TJ
,
Rupprecht
LE
,
Hayes
MR
,
Blendy
JA
,
Schmidt
HD
.
Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats
.
Neuropsychopharmacology
.
2012
Sep
;
37
(
10
):
2310
21
.
[PubMed]
0893-133X
38.
Caggiula
AR
,
Donny
EC
,
White
AR
,
Chaudhri
N
,
Booth
S
,
Gharib
MA
, et al.
Cue dependency of nicotine self-administration and smoking
.
Pharmacol Biochem Behav
.
2001
Dec
;
70
(
4
):
515
30
.
[PubMed]
0091-3057
39.
Epstein
DH
,
Preston
KL
,
Stewart
J
,
Shaham
Y
.
Toward a model of drug relapse: an assessment of the validity of the reinstatement procedure
.
Psychopharmacology (Berl)
.
2006
Nov
;
189
(
1
):
1
16
.
[PubMed]
0033-3158
40.
O’Connor
EC
,
Parker
D
,
Rollema
H
,
Mead
AN
.
The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats
.
Psychopharmacology (Berl)
.
2010
Feb
;
208
(
3
):
365
76
.
[PubMed]
0033-3158
41.
Le Foll
B
,
Chakraborty-Chatterjee
M
,
Lev-Ran
S
,
Barnes
C
,
Pushparaj
A
,
Gamaleddin
I
, et al.
Varenicline decreases nicotine self-administration and cue-induced reinstatement of nicotine-seeking behaviour in rats when a long pretreatment time is used
.
Int J Neuropsychopharmacol
.
2012
Oct
;
15
(
9
):
1265
74
.
[PubMed]
1461-1457
42.
Hays
JT
,
Ebbert
JO
,
Sood
A
.
Efficacy and safety of varenicline for smoking cessation
.
Am J Med
.
2008
Apr
;
121
(
4
Suppl 1
):
S32
42
.
[PubMed]
0002-9343
43.
Mansvelder
HD
,
McGehee
DS
.
Long-term potentiation of excitatory inputs to brain reward areas by nicotine
.
Neuron
.
2000
Aug
;
27
(
2
):
349
57
.
[PubMed]
0896-6273
44.
Liu
L
,
Zhao-Shea
R
,
McIntosh
JM
,
Gardner
PD
,
Tapper
AR
.
Nicotine persistently activates ventral tegmental area dopaminergic neurons via nicotinic acetylcholine receptors containing α4 and α6 subunits
.
Mol Pharmacol
.
2012
Apr
;
81
(
4
):
541
8
.
[PubMed]
0026-895X
45.
Saal
D
,
Dong
Y
,
Bonci
A
,
Malenka
RC
.
Drugs of abuse and stress trigger a common synaptic adaptation in dopamine neurons
.
Neuron
.
2003
Feb
;
37
(
4
):
577
82
.
[PubMed]
0896-6273
46.
Zhang
H
,
Sulzer
D
.
Frequency-dependent modulation of dopamine release by nicotine
.
Nat Neurosci
.
2004
Jun
;
7
(
6
):
581
2
.
[PubMed]
1097-6256
47.
Rice
ME
,
Cragg
SJ
.
Nicotine amplifies reward-related dopamine signals in striatum
.
Nat Neurosci
.
2004
Jun
;
7
(
6
):
583
4
.
[PubMed]
1097-6256
48.
Pierce
RC
,
Kumaresan
V
.
The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?
Neurosci Biobehav Rev
.
2006
;
30
(
2
):
215
38
.
[PubMed]
0149-7634
49.
Laviolette
SR
,
van der Kooy
D
.
The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour
.
Nat Rev Neurosci
.
2004
Jan
;
5
(
1
):
55
65
.
[PubMed]
1471-003X
50.
Damsma
G
,
Day
J
,
Fibiger
HC
.
Lack of tolerance to nicotine-induced dopamine release in the nucleus accumbens
.
Eur J Pharmacol
.
1989
Sep
;
168
(
3
):
363
8
.
[PubMed]
0014-2999
51.
Benwell
ME
,
Balfour
DJ
,
Lucchi
HM
.
Influence of tetrodotoxin and calcium on changes in extracellular dopamine levels evoked by systemic nicotine
.
Psychopharmacology (Berl)
.
1993
;
112
(
4
):
467
74
.
[PubMed]
0033-3158
52.
Nisell
M
,
Nomikos
GG
,
Svensson
TH
.
Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area
.
Synapse
.
1994
Jan
;
16
(
1
):
36
44
.
[PubMed]
0887-4476
53.
Pontieri
FE
,
Tanda
G
,
Orzi
F
,
Di Chiara
G
.
Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs
.
Nature
.
1996
Jul
;
382
(
6588
):
255
7
.
[PubMed]
0028-0836
54.
Ferrari
R
,
Le Novère
N
,
Picciotto
MR
,
Changeux
JP
,
Zoli
M
.
Acute and long-term changes in the mesolimbic dopamine pathway after systemic or local single nicotine injections
.
Eur J Neurosci
.
2002
Jun
;
15
(
11
):
1810
8
.
[PubMed]
0953-816X
55.
Mifsud
JC
,
Hernandez
L
,
Hoebel
BG
.
Nicotine infused into the nucleus accumbens increases synaptic dopamine as measured by in vivo microdialysis
.
Brain Res
.
1989
Jan
;
478
(
2
):
365
7
.
[PubMed]
0006-8993
56.
Rahman
S
,
Zhang
J
,
Engleman
EA
,
Corrigall
WA
.
Neuroadaptive changes in the mesoaccumbens dopamine system after chronic nicotine self-administration: a microdialysis study
.
Neuroscience
.
2004
;
129
(
2
):
415
24
.
[PubMed]
0306-4522
57.
Mameli-Engvall
M
,
Evrard
A
,
Pons
S
,
Maskos
U
,
Svensson
TH
,
Changeux
JP
, et al.
Hierarchical control of dopamine neuron-firing patterns by nicotinic receptors
.
Neuron
.
2006
Jun
;
50
(
6
):
911
21
.
[PubMed]
0896-6273
58.
Picciotto
MR
,
Zoli
M
,
Rimondini
R
,
Léna
C
,
Marubio
LM
,
Pich
EM
, et al.
Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine
.
Nature
.
1998
Jan
;
391
(
6663
):
173
7
.
[PubMed]
0028-0836
59.
Changeux
JP
.
Nicotine addiction and nicotinic receptors: lessons from genetically modified mice
.
Nat Rev Neurosci
.
2010
Jun
;
11
(
6
):
389
401
.
[PubMed]
1471-003X
60.
Li
X
, et al.
Involvement of glutamatergic and GABAergic systems in nicotine dependence: Implications for novel pharmacotherapies for smoking cessation. Neuropharmacology,
2014
. 76 Pt B: p. 554-65.
61.
Liechti
ME
,
Markou
A
.
Role of the glutamatergic system in nicotine dependence : implications for the discovery and development of new pharmacological smoking cessation therapies
.
CNS Drugs
.
2008
;
22
(
9
):
705
24
.
[PubMed]
1172-7047
62.
Kalivas
PW
.
The glutamate homeostasis hypothesis of addiction
.
Nat Rev Neurosci
.
2009
Aug
;
10
(
8
):
561
72
.
[PubMed]
1471-003X
63.
Fu
Y
,
Matta
SG
,
Gao
W
,
Brower
VG
,
Sharp
BM
.
Systemic nicotine stimulates dopamine release in nucleus accumbens: re-evaluation of the role of N-methyl-D-aspartate receptors in the ventral tegmental area
.
J Pharmacol Exp Ther
.
2000
Aug
;
294
(
2
):
458
65
.
[PubMed]
0022-3565
64.
Civelli
O
,
Bunzow
JR
,
Grandy
DK
.
Molecular diversity of the dopamine receptors
.
Annu Rev Pharmacol Toxicol
.
1993
;
33
(
1
):
281
307
.
[PubMed]
0362-1642
65.
Missale
C
,
Nash
SR
,
Robinson
SW
,
Jaber
M
,
Caron
MG
.
Dopamine receptors: from structure to function
.
Physiol Rev
.
1998
Jan
;
78
(
1
):
189
225
.
[PubMed]
0031-9333
66.
Seeman
P
,
Van Tol
HH
.
Dopamine receptor pharmacology
.
Curr Opin Neurol Neurosurg
.
1993
Aug
;
6
(
4
):
602
8
.
[PubMed]
0951-7383
67.
Liu
X
,
Jernigen
C
,
Gharib
M
,
Booth
S
,
Caggiula
AR
,
Sved
AF
.
Effects of dopamine antagonists on drug cue-induced reinstatement of nicotine-seeking behavior in rats
.
Behav Pharmacol
.
2010
Mar
;
21
(
2
):
153
60
.
[PubMed]
0955-8810
68.
Hutchison
KE
,
LaChance
H
,
Niaura
R
,
Bryan
A
,
Smolen
A
.
The DRD4 VNTR polymorphism influences reactivity to smoking cues
.
J Abnorm Psychol
.
2002
Feb
;
111
(
1
):
134
43
.
[PubMed]
0021-843X
69.
McClernon
FJ
,
Hutchison
KE
,
Rose
JE
,
Kozink
RV
.
DRD4 VNTR polymorphism is associated with transient fMRI-BOLD responses to smoking cues
.
Psychopharmacology (Berl)
.
2007
Nov
;
194
(
4
):
433
41
.
[PubMed]
0033-3158
70.
Munafò
MR
,
Johnstone
EC
.
Smoking status moderates the association of the dopamine D4 receptor (DRD4) gene VNTR polymorphism with selective processing of smoking-related cues
.
Addict Biol
.
2008
Sep
;
13
(
3-4
):
435
9
.
[PubMed]
1355-6215
71.
Yan
Y
,
Pushparaj
A
,
Le Strat
Y
,
Gamaleddin
I
,
Barnes
C
,
Justinova
Z
, et al.
Blockade of dopamine d4 receptors attenuates reinstatement of extinguished nicotine-seeking behavior in rats
.
Neuropsychopharmacology
.
2012
Feb
;
37
(
3
):
685
96
.
[PubMed]
0893-133X
72.
Andreoli
,
M.
, et al.
,
Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
2003
. 28(7): p. 1272-80.
73.
Micheli
F
,
Bonanomi
G
,
Blaney
FE
,
Braggio
S
,
Capelli
AM
,
Checchia
A
, et al.
1,2,4-triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D(3) receptor antagonists
.
J Med Chem
.
2007
Oct
;
50
(
21
):
5076
89
.
[PubMed]
0022-2623
74.
Khaled
MA
,
Farid Araki
K
,
Li
B
,
Coen
KM
,
Marinelli
PW
,
Varga
J
, et al.
The selective dopamine D3 receptor antagonist SB 277011-A, but not the partial agonist BP 897, blocks cue-induced reinstatement of nicotine-seeking
.
Int J Neuropsychopharmacol
.
2010
Mar
;
13
(
2
):
181
90
.
[PubMed]
1461-1457
75.
Le Foll
B
,
Diaz
J
,
Sokoloff
P
.
Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats
.
Synapse
.
2003
Mar
;
47
(
3
):
176
83
.
[PubMed]
0887-4476
76.
Diaz
J
,
Lévesque
D
,
Lammers
CH
,
Griffon
N
,
Martres
MP
,
Schwartz
JC
, et al.
Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain
.
Neuroscience
.
1995
Apr
;
65
(
3
):
731
45
.
[PubMed]
0306-4522
77.
Bouthenet
ML
,
Souil
E
,
Martres
MP
,
Sokoloff
P
,
Giros
B
,
Schwartz
JC
.
Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA
.
Brain Res
.
1991
Nov
;
564
(
2
):
203
19
.
[PubMed]
0006-8993
78.
Sokoloff
P
,
Giros
B
,
Martres
MP
,
Bouthenet
ML
,
Schwartz
JC
.
Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics
.
Nature
.
1990
Sep
;
347
(
6289
):
146
51
.
[PubMed]
0028-0836
79.
Scherma
M
,
Panlilio
LV
,
Fadda
P
,
Fattore
L
,
Gamaleddin
I
,
Le Foll
B
, et al.
Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3′-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats
.
J Pharmacol Exp Ther
.
2008
Nov
;
327
(
2
):
482
90
.
[PubMed]
0022-3565
80.
Melis
M
,
Pillolla
G
,
Luchicchi
A
,
Muntoni
AL
,
Yasar
S
,
Goldberg
SR
, et al.
Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors
.
J Neurosci
.
2008
Dec
;
28
(
51
):
13985
94
.
[PubMed]
0270-6474
81.
Forget
B
,
Coen
KM
,
Le Foll
B
.
Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration—comparison with CB(1) receptor blockade
.
Psychopharmacology (Berl)
.
2009
Sep
;
205
(
4
):
613
24
.
[PubMed]
0033-3158
82.
Mascia
P
,
Pistis
M
,
Justinova
Z
,
Panlilio
LV
,
Luchicchi
A
,
Lecca
S
, et al.
Blockade of nicotine reward and reinstatement by activation of alpha-type peroxisome proliferator-activated receptors
.
Biol Psychiatry
.
2011
Apr
;
69
(
7
):
633
41
.
[PubMed]
0006-3223
83.
Panlilio
LV
,
Justinova
Z
,
Mascia
P
,
Pistis
M
,
Luchicchi
A
,
Lecca
S
, et al.
Novel use of a lipid-lowering fibrate medication to prevent nicotine reward and relapse: preclinical findings
.
Neuropsychopharmacology
.
2012
Jul
;
37
(
8
):
1838
47
.
[PubMed]
0893-133X
84.
Gipson
CD
,
Reissner
KJ
,
Kupchik
YM
,
Smith
AC
,
Stankeviciute
N
,
Hensley-Simon
ME
, et al.
Reinstatement of nicotine seeking is mediated by glutamatergic plasticity
.
Proc Natl Acad Sci USA
.
2013
May
;
110
(
22
):
9124
9
.
[PubMed]
0027-8424
85.
Lewerenz
J
,
Hewett
SJ
,
Huang
Y
,
Lambros
M
,
Gout
PW
,
Kalivas
PW
, et al.
The cystine/glutamate antiporter system x(c)(-) in health and disease: from molecular mechanisms to novel therapeutic opportunities
.
Antioxid Redox Signal
.
2013
Feb
;
18
(
5
):
522
55
.
[PubMed]
1523-0864
86.
Knackstedt
LA
,
LaRowe
S
,
Mardikian
P
,
Malcolm
R
,
Upadhyaya
H
,
Hedden
S
, et al.
The role of cystine-glutamate exchange in nicotine dependence in rats and humans
.
Biol Psychiatry
.
2009
May
;
65
(
10
):
841
5
.
[PubMed]
0006-3223
87.
Ramirez-Niño
AM
,
D’Souza
MS
,
Markou
A
.
N-acetylcysteine decreased nicotine self-administration and cue-induced reinstatement of nicotine seeking in rats: comparison with the effects of N-acetylcysteine on food responding and food seeking
.
Psychopharmacology (Berl)
.
2013
Jan
;
225
(
2
):
473
82
.
[PubMed]
0033-3158
88.
Moro
F
, et al.
mGluR2/3 mediates short-term control of nicotine-seeking by acute systemic N-acetylcysteine
.
Addict Biol
.
2016
.
[PubMed]
1355-6215
89.
McClure
EA
,
Baker
NL
,
Gipson
CD
,
Carpenter
MJ
,
Roper
AP
,
Froeliger
BE
, et al.
An open-label pilot trial of N-acetylcysteine and varenicline in adult cigarette smokers
.
Am J Drug Alcohol Abuse
.
2015
Jan
;
41
(
1
):
52
6
.
[PubMed]
0095-2990
90.
D’Souza
MS
,
Markou
A
.
Differential role of N-methyl-D-aspartate receptor-mediated glutamate transmission in the nucleus accumbens shell and core in nicotine seeking in rats
.
Eur J Neurosci
.
2014
Apr
;
39
(
8
):
1314
22
.
[PubMed]
0953-816X
91.
Bespalov
AY
,
Dravolina
OA
,
Sukhanov
I
,
Zakharova
E
,
Blokhina
E
,
Zvartau
E
, et al.
Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cue- and schedule-induced reinstatement of nicotine self-administration behavior in rats
.
Neuropharmacology
.
2005
;
49
Suppl 1
:
167
78
.
[PubMed]
0028-3908
92.
Dravolina
OA
,
Zakharova
ES
,
Shekunova
EV
,
Zvartau
EE
,
Danysz
W
,
Bespalov
AY
.
mGlu1 receptor blockade attenuates cue- and nicotine-induced reinstatement of extinguished nicotine self-administration behavior in rats
.
Neuropharmacology
.
2007
Feb
;
52
(
2
):
263
9
.
[PubMed]
0028-3908
93.
Liechti
ME
,
Lhuillier
L
,
Kaupmann
K
,
Markou
A
.
Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence
.
J Neurosci
.
2007
Aug
;
27
(
34
):
9077
85
.
[PubMed]
0270-6474
94.
Justinova
Z
,
Panlilio
LV
,
Secci
ME
,
Redhi
GH
,
Schindler
CW
,
Cross
AJ
, et al.
The Novel Metabotropic Glutamate Receptor 2 Positive Allosteric Modulator, AZD8529, Decreases Nicotine Self-Administration and Relapse in Squirrel Monkeys
.
Biol Psychiatry
.
2015
Oct
;
78
(
7
):
452
62
.
[PubMed]
0006-3223
95.
Li
X
,
D’Souza
MS
,
Niño
AM
,
Doherty
J
,
Cross
A
,
Markou
A
.
Attenuation of nicotine-taking and nicotine-seeking behavior by the mGlu2 receptor positive allosteric modulators AZD8418 and AZD8529 in rats
.
Psychopharmacology (Berl)
.
2016
May
;
233
(
10
):
1801
14
.
[PubMed]
0033-3158
96.
Acri
,
J.B.
,
A.J.
Cross
, and
P.
Skolnick
, From bench to bedside: mGluR2 positive allosteric modulators as medications to treat substance use disorders. Psychopharmacology (Berl),
2016
.
97.
Coe
JW
,
Brooks
PR
,
Vetelino
MG
,
Wirtz
MC
,
Arnold
EP
,
Huang
J
, et al.
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation
.
J Med Chem
.
2005
May
;
48
(
10
):
3474
7
.
[PubMed]
0022-2623
98.
Wouda
JA
,
Riga
D
,
De Vries
W
,
Stegeman
M
,
van Mourik
Y
,
Schetters
D
, et al.
Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control
.
Psychopharmacology (Berl)
.
2011
Jul
;
216
(
2
):
267
77
.
[PubMed]
0033-3158
99.
Liu
X
.
Effects of blockade of α4β2 and α7 nicotinic acetylcholine receptors on cue-induced reinstatement of nicotine-seeking behaviour in rats
.
Int J Neuropsychopharmacol
.
2014
Jan
;
17
(
1
):
105
16
.
[PubMed]
1461-1457
100.
Li
S
,
Li
Z
,
Pei
L
,
Le
AD
,
Liu
F
.
The α7nACh-NMDA receptor complex is involved in cue-induced reinstatement of nicotine seeking
.
J Exp Med
.
2012
Nov
;
209
(
12
):
2141
7
.
[PubMed]
0022-1007
101.
Lee
AM
,
Arreola
AC
,
Kimmey
BA
,
Schmidt
HD
.
Administration of the nicotinic acetylcholine receptor agonists ABT-089 and ABT-107 attenuates the reinstatement of nicotine-seeking behavior in rats
.
Behav Brain Res
.
2014
Nov
;
274
:
168
75
.
[PubMed]
0166-4328
102.
Cippitelli
A
,
Wu
J
,
Gaiolini
KA
,
Mercatelli
D
,
Schoch
J
,
Gorman
M
, et al.
AT-1001: a high-affinity α3β4 nAChR ligand with novel nicotine-suppressive pharmacology
.
Br J Pharmacol
.
2015
Apr
;
172
(
7
):
1834
45
.
[PubMed]
0007-1188
103.
Williams
DK
,
Wang
J
,
Papke
RL
.
Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations
.
Biochem Pharmacol
.
2011
Oct
;
82
(
8
):
915
30
.
[PubMed]
0006-2952
104.
Nelson
ME
,
Kuryatov
A
,
Choi
CH
,
Zhou
Y
,
Lindstrom
J
.
Alternate stoichiometries of alpha4beta2 nicotinic acetylcholine receptors
.
Mol Pharmacol
.
2003
Feb
;
63
(
2
):
332
41
.
[PubMed]
0026-895X
105.
Moroni
M
,
Zwart
R
,
Sher
E
,
Cassels
BK
,
Bermudez
I
.
alpha4beta2 nicotinic receptors with high and low acetylcholine sensitivity: pharmacology, stoichiometry, and sensitivity to long-term exposure to nicotine
.
Mol Pharmacol
.
2006
Aug
;
70
(
2
):
755
68
.
[PubMed]
0026-895X
106.
Anderson
DJ
,
Malysz
J
,
Grønlien
JH
,
El Kouhen
R
,
Håkerud
M
,
Wetterstrand
C
, et al.
Stimulation of dopamine release by nicotinic acetylcholine receptor ligands in rat brain slices correlates with the profile of high, but not low, sensitivity alpha4beta2 subunit combination
.
Biochem Pharmacol
.
2009
Oct
;
78
(
7
):
844
51
.
[PubMed]
0006-2952
107.
Harmey
D
,
Griffin
PR
,
Kenny
PJ
.
Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions
.
Nicotine Tob Res
.
2012
Nov
;
14
(
11
):
1300
18
.
[PubMed]
1462-2203
108.
Maurer
JJ
,
Sandager-Nielsen
K
,
Schmidt
HD
.
Attenuation of nicotine taking and seeking in rats by the stoichiometry-selective alpha4beta2 nicotinic acetylcholine receptor positive allosteric modulator NS9283
.
Psychopharmacology (Berl)
.
2017
Feb
;
234
(
3
):
475
84
.
[PubMed]
0033-3158
109.
Harvey
AL
.
The pharmacology of galanthamine and its analogues
.
Pharmacol Ther
.
1995
;
68
(
1
):
113
28
.
[PubMed]
0163-7258
110.
Kosasa
T
,
Kuriya
Y
,
Matsui
K
,
Yamanishi
Y
.
Inhibitory effects of donepezil hydrochloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rats
.
Eur J Pharmacol
.
1999
Dec
;
386
(
1
):
7
13
.
[PubMed]
0014-2999
111.
Kimmey
BA
,
Rupprecht
LE
,
Hayes
MR
,
Schmidt
HD
.
Donepezil, an acetylcholinesterase inhibitor, attenuates nicotine self-administration and reinstatement of nicotine seeking in rats
.
Addict Biol
.
2014
Jul
;
19
(
4
):
539
51
.
[PubMed]
1355-6215
112.
Ashare
RL
,
Kimmey
BA
,
Rupprecht
LE
,
Bowers
ME
,
Hayes
MR
,
Schmidt
HD
.
Repeated administration of an acetylcholinesterase inhibitor attenuates nicotine taking in rats and smoking behavior in human smokers
.
Transl Psychiatry
.
2016
Jan
;
6
(
1
):
e713
.
[PubMed]
2158-3188
113.
Wilkinson
DS
,
Gould
TJ
.
The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice
.
Behav Brain Res
.
2011
Sep
;
223
(
1
):
53
7
.
[PubMed]
0166-4328
114.
Sofuoglu
M
,
Herman
AI
,
Li
Y
,
Waters
AJ
.
Galantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette smokers: a preliminary report
.
Psychopharmacology (Berl)
.
2012
Dec
;
224
(
3
):
413
20
.
[PubMed]
0033-3158
115.
Loughead
J
,
Wileyto
EP
,
Ruparel
K
,
Falcone
M
,
Hopson
R
,
Gur
R
, et al.
Working memory-related neural activity predicts future smoking relapse
.
Neuropsychopharmacology
.
2015
May
;
40
(
6
):
1311
20
.
[PubMed]
0893-133X
116.
Patterson
F
,
Jepson
C
,
Loughead
J
,
Perkins
K
,
Strasser
AA
,
Siegel
S
, et al.
Working memory deficits predict short-term smoking resumption following brief abstinence
.
Drug Alcohol Depend
.
2010
Jan
;
106
(
1
):
61
4
.
[PubMed]
0376-8716
117.
Ashare
RL
,
Schmidt
HD
.
Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal
.
Expert Opin Drug Discov
.
2014
Jun
;
9
(
6
):
579
94
.
[PubMed]
1746-0441
118.
van Zessen
R
,
Phillips
JL
,
Budygin
EA
,
Stuber
GD
.
Activation of VTA GABA neurons disrupts reward consumption
.
Neuron
.
2012
Mar
;
73
(
6
):
1184
94
.
[PubMed]
0896-6273
119.
Morales
M
,
Margolis
EB
.
Ventral tegmental area: cellular heterogeneity, connectivity and behaviour
.
Nat Rev Neurosci
.
2017
Feb
;
18
(
2
):
73
85
.
[PubMed]
1471-003X
120.
Paterson
NE
,
Froestl
W
,
Markou
A
.
Repeated administration of the GABAB receptor agonist CGP44532 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine-seeking in rats
.
Neuropsychopharmacology
.
2005
Jan
;
30
(
1
):
119
28
.
[PubMed]
0893-133X
121.
Fattore
L
,
Spano
MS
,
Cossu
G
,
Scherma
M
,
Fratta
W
,
Fadda
P
.
Baclofen prevents drug-induced reinstatement of extinguished nicotine-seeking behaviour and nicotine place preference in rodents
.
Eur Neuropsychopharmacol
.
2009
Jul
;
19
(
7
):
487
98
.
[PubMed]
0924-977X
122.
Franklin
TR
,
Harper
D
,
Kampman
K
,
Kildea-McCrea
S
,
Jens
W
,
Lynch
KG
, et al.
The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study
.
Drug Alcohol Depend
.
2009
Jul
;
103
(
1-2
):
30
6
.
[PubMed]
0376-8716
123.
Ong
J
,
Kerr
DI
.
Clinical potential of GABAB receptor modulators
.
CNS Drug Rev
.
2005
;
11
(
3
):
317
34
.
[PubMed]
1080-563X
124.
Urwyler
S
,
Pozza
MF
,
Lingenhoehl
K
,
Mosbacher
J
,
Lampert
C
,
Froestl
W
, et al.
N,N′-Dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6-diamine (GS39783) and structurally related compounds: novel allosteric enhancers of gamma-aminobutyric acidB receptor function
.
J Pharmacol Exp Ther
.
2003
Oct
;
307
(
1
):
322
30
.
[PubMed]
0022-3565
125.
Vlachou
S
,
Guery
S
,
Froestl
W
,
Banerjee
D
,
Benedict
J
,
Finn
MG
, et al.
Repeated administration of the GABAB receptor positive modulator BHF177 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine seeking in rats
.
Psychopharmacology (Berl)
.
2011
May
;
215
(
1
):
117
28
.
[PubMed]
0033-3158
126.
Lubbers
BR
,
van Mourik
Y
,
Schetters
D
,
Smit
AB
,
De Vries
TJ
,
Spijker
S
.
Prefrontal gamma-aminobutyric acid type A receptor insertion controls cue-induced relapse to nicotine seeking
.
Biol Psychiatry
.
2014
Nov
;
76
(
9
):
750
8
.
[PubMed]
0006-3223
127.
Wiskerke
J
,
Pattij
T
,
Schoffelmeer
AN
,
De Vries
TJ
.
The role of CB1 receptors in psychostimulant addiction
.
Addict Biol
.
2008
Jun
;
13
(
2
):
225
38
.
[PubMed]
1355-6215
128.
Panagis
G
,
Mackey
B
,
Vlachou
S
.
Cannabinoid Regulation of Brain Reward Processing with an Emphasis on the Role of CB1 Receptors: A Step Back into the Future
.
Front Psychiatry
.
2014
Jul
;
5
:
92
.
[PubMed]
1664-0640
129.
De Vries
TJ
,
de Vries
W
,
Janssen
MC
,
Schoffelmeer
AN
.
Suppression of conditioned nicotine and sucrose seeking by the cannabinoid-1 receptor antagonist SR141716A
.
Behav Brain Res
.
2005
Jun
;
161
(
1
):
164
8
.
[PubMed]
0166-4328
130.
Diergaarde
L
,
de Vries
W
,
Raasø
H
,
Schoffelmeer
AN
,
De Vries
TJ
.
Contextual renewal of nicotine seeking in rats and its suppression by the cannabinoid-1 receptor antagonist Rimonabant (SR141716A)
.
Neuropharmacology
.
2008
Oct
;
55
(
5
):
712
6
.
[PubMed]
0028-3908
131.
Schindler
CW
,
Redhi
GH
,
Vemuri
K
,
Makriyannis
A
,
Le Foll
B
,
Bergman
J
, et al.
Blockade of Nicotine and Cannabinoid Reinforcement and Relapse by a Cannabinoid CB1-Receptor Neutral Antagonist AM4113 and Inverse Agonist Rimonabant in Squirrel Monkeys
.
Neuropsychopharmacology
.
2016
Aug
;
41
(
9
):
2283
93
.
[PubMed]
0893-133X
132.
Shoaib
M
.
The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats
.
Neuropharmacology
.
2008
Feb
;
54
(
2
):
438
44
.
[PubMed]
0028-3908
133.
Gamaleddin
I
,
Zvonok
A
,
Makriyannis
A
,
Goldberg
SR
,
Le Foll
B
.
Effects of a selective cannabinoid CB2 agonist and antagonist on intravenous nicotine self administration and reinstatement of nicotine seeking
.
PLoS One
.
2012
;
7
(
1
):
e29900
.
[PubMed]
1932-6203
134.
Justinova
Z
,
Panlilio
LV
,
Moreno-Sanz
G
,
Redhi
GH
,
Auber
A
,
Secci
ME
, et al.
Effects of Fatty Acid Amide Hydrolase (FAAH) Inhibitors in Non-Human Primate Models of Nicotine Reward and Relapse
.
Neuropsychopharmacology
.
2015
Aug
;
40
(
9
):
2185
97
.
[PubMed]
0893-133X
135.
Justinova
Z
,
Mangieri
RA
,
Bortolato
M
,
Chefer
SI
,
Mukhin
AG
,
Clapper
JR
, et al.
Fatty acid amide hydrolase inhibition heightens anandamide signaling without producing reinforcing effects in primates
.
Biol Psychiatry
.
2008
Dec
;
64
(
11
):
930
7
.
[PubMed]
0006-3223
136.
Fegley
D
,
Gaetani
S
,
Duranti
A
,
Tontini
A
,
Mor
M
,
Tarzia
G
, et al.
Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation
.
J Pharmacol Exp Ther
.
2005
Apr
;
313
(
1
):
352
8
.
[PubMed]
0022-3565
137.
Forget
B
,
Guranda
M
,
Gamaleddin
I
,
Goldberg
SR
,
Le Foll
B
.
Attenuation of cue-induced reinstatement of nicotine seeking by URB597 through cannabinoid CB1 receptor in rats
.
Psychopharmacology (Berl)
.
2016
May
;
233
(
10
):
1823
8
.
[PubMed]
0033-3158
138.
Gamaleddin
I
,
Guranda
M
,
Goldberg
SR
,
Le Foll
B
.
The selective anandamide transport inhibitor VDM11 attenuates reinstatement of nicotine seeking behaviour, but does not affect nicotine intake
.
Br J Pharmacol
.
2011
Nov
;
164
(
6
):
1652
60
.
[PubMed]
0007-1188
139.
Gamaleddin
I
,
Guranda
M
,
Scherma
M
,
Fratta
W
,
Makriyannis
A
,
Vadivel
SK
, et al.
AM404 attenuates reinstatement of nicotine seeking induced by nicotine-associated cues and nicotine priming but does not affect nicotine- and food-taking
.
J Psychopharmacol
.
2013
Jun
;
27
(
6
):
564
71
.
[PubMed]
0269-8811
140.
Scherma
M
,
Justinová
Z
,
Zanettini
C
,
Panlilio
LV
,
Mascia
P
,
Fadda
P
, et al.
The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine-induced dopamine elevations in the nucleus accumbens shell in rats
.
Br J Pharmacol
.
2012
Apr
;
165
(
8
):
2539
48
.
[PubMed]
0007-1188
141.
Mantsch
JR
,
Baker
DA
,
Funk
D
,
AD
,
Shaham
Y
.
Stress-Induced Reinstatement of Drug Seeking: 20 Years of Progress
.
Neuropsychopharmacology
.
2016
Jan
;
41
(
1
):
335
56
.
[PubMed]
0893-133X
142.
Zislis
G
,
Desai
TV
,
Prado
M
,
Shah
HP
,
Bruijnzeel
AW
.
Effects of the CRF receptor antagonist D-Phe CRF(12-41) and the alpha2-adrenergic receptor agonist clonidine on stress-induced reinstatement of nicotine-seeking behavior in rats
.
Neuropharmacology
.
2007
Dec
;
53
(
8
):
958
66
.
[PubMed]
0028-3908
143.
Yamada
H
,
Bruijnzeel
AW
.
Stimulation of α2-adrenergic receptors in the central nucleus of the amygdala attenuates stress-induced reinstatement of nicotine seeking in rats
.
Neuropharmacology
.
2011
Feb-Mar
;
60
(
2-3
):
303
11
.
[PubMed]
0028-3908
144.
Forget
B
,
Wertheim
C
,
Mascia
P
,
Pushparaj
A
,
Goldberg
SR
,
Le Foll
B
.
Noradrenergic alpha1 receptors as a novel target for the treatment of nicotine addiction
.
Neuropsychopharmacology
.
2010
Jul
;
35
(
8
):
1751
60
.
[PubMed]
0893-133X
145.
McKee
SA
,
Potenza
MN
,
Kober
H
,
Sofuoglu
M
,
Arnsten
AF
,
Picciotto
MR
, et al.
A translational investigation targeting stress-reactivity and prefrontal cognitive control with guanfacine for smoking cessation
.
J Psychopharmacol
.
2015
Mar
;
29
(
3
):
300
11
.
[PubMed]
0269-8811
146.
Fox
HC
,
Seo
D
,
Tuit
K
,
Hansen
J
,
Kimmerling
A
,
Morgan
PT
, et al.
Guanfacine effects on stress, drug craving and prefrontal activation in cocaine dependent individuals: preliminary findings
.
J Psychopharmacol
.
2012
Jul
;
26
(
7
):
958
72
.
[PubMed]
0269-8811
147.
Fox
HC
,
Morgan
PT
,
Sinha
R
.
Sex differences in guanfacine effects on drug craving and stress arousal in cocaine-dependent individuals
.
Neuropsychopharmacology
.
2014
May
;
39
(
6
):
1527
37
.
[PubMed]
0893-133X
148.
Chiamulera
C
,
Tedesco
V
,
Zangrandi
L
,
Giuliano
C
,
Fumagalli
G
.
Propranolol transiently inhibits reinstatement of nicotine-seeking behaviour in rats
.
J Psychopharmacol
.
2010
Mar
;
24
(
3
):
389
95
.
[PubMed]
0269-8811
149.
Xue
YX
,
Deng
JH
,
Chen
YY
,
Zhang
LB
,
Wu
P
,
Huang
GD
, et al.
Effect of Selective Inhibition of Reactivated Nicotine-Associated Memories With Propranolol on Nicotine Craving
.
JAMA Psychiatry
.
2017
Mar
;
74
(
3
):
224
32
.
[PubMed]
2168-622X
150.
Fletcher
PJ
,
Rizos
Z
,
Noble
K
,
Soko
AD
,
Silenieks
LB
,
AD
, et al.
Effects of the 5-HT2C receptor agonist Ro60-0175 and the 5-HT2A receptor antagonist M100907 on nicotine self-administration and reinstatement
.
Neuropharmacology
.
2012
Jun
;
62
(
7
):
2288
98
.
[PubMed]
0028-3908
151.
Ichikawa
J
,
Kuroki
T
,
Kitchen
MT
,
Meltzer
HY
.
R(+)-8-OH-DPAT, a 5-HT1A receptor agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbens
.
Eur J Pharmacol
.
1995
Dec
;
287
(
2
):
179
84
.
[PubMed]
0014-2999
152.
Pehek
EA
,
McFarlane
HG
,
Maguschak
K
,
Price
B
,
Pluto
CP
.
M100,907, a selective 5-HT(2A) antagonist, attenuates dopamine release in the rat medial prefrontal cortex
.
Brain Res
.
2001
Jan
;
888
(
1
):
51
9
.
[PubMed]
0006-8993
153.
Yan
Q
,
Reith
ME
,
Yan
S
.
Enhanced accumbal dopamine release following 5-HT(2A) receptor stimulation in rats pretreated with intermittent cocaine
.
Brain Res
.
2000
Apr
;
863
(
1-2
):
254
8
.
[PubMed]
0006-8993
154.
Auclair
A
,
Blanc
G
,
Glowinski
J
,
Tassin
JP
.
Role of serotonin 2A receptors in the D-amphetamine-induced release of dopamine: comparison with previous data on alpha1b-adrenergic receptors
.
J Neurochem
.
2004
Oct
;
91
(
2
):
318
26
.
[PubMed]
0022-3042
155.
Porras
G
,
Di Matteo
V
,
Fracasso
C
,
Lucas
G
,
De Deurwaerdère
P
,
Caccia
S
, et al.
5-HT2A and 5-HT2C/2B receptor subtypes modulate dopamine release induced in vivo by amphetamine and morphine in both the rat nucleus accumbens and striatum
.
Neuropsychopharmacology
.
2002
Mar
;
26
(
3
):
311
24
.
[PubMed]
0893-133X
156.
De Deurwaerdere
P
,
Di Giovanni
G
.
Serotonergic modulation of the activity of mesencephalic dopaminergic systems: therapeutic implications
.
Prog Neurobiol
.
2016
.
[PubMed]
0301-0082
157.
Bruijnzeel
,
A.W.
,
Neuropeptide systems and new treatments for nicotine addiction.
Psychopharmacology (Berl),
2016
.
158.
Shippenberg
TS
,
Zapata
A
,
Chefer
VI
.
Dynorphin and the pathophysiology of drug addiction
.
Pharmacol Ther
.
2007
Nov
;
116
(
2
):
306
21
.
[PubMed]
0163-7258
159.
Van’t Veer
A
,
Carlezon
WA
 Jr
.
Role of kappa-opioid receptors in stress and anxiety-related behavior
.
Psychopharmacology (Berl)
.
2013
Oct
;
229
(
3
):
435
52
.
[PubMed]
0033-3158
160.
Grella
SL
,
Funk
D
,
Coen
K
,
Li
Z
,
AD
.
Role of the kappa-opioid receptor system in stress-induced reinstatement of nicotine seeking in rats
.
Behav Brain Res
.
2014
May
;
265
:
188
97
.
[PubMed]
0166-4328
161.
Liu
X
,
Palmatier
MI
,
Caggiula
AR
,
Sved
AF
,
Donny
EC
,
Gharib
M
, et al.
Naltrexone attenuation of conditioned but not primary reinforcement of nicotine in rats
.
Psychopharmacology (Berl)
.
2009
Mar
;
202
(
4
):
589
98
.
[PubMed]
0033-3158
162.
Bruijnzeel
AW
,
Prado
M
,
Isaac
S
.
Corticotropin-releasing factor-1 receptor activation mediates nicotine withdrawal-induced deficit in brain reward function and stress-induced relapse
.
Biol Psychiatry
.
2009
Jul
;
66
(
2
):
110
7
.
[PubMed]
0006-3223
163.
Plaza-Zabala
A
,
Martín-García
E
,
de Lecea
L
,
Maldonado
R
,
Berrendero
F
.
Hypocretins regulate the anxiogenic-like effects of nicotine and induce reinstatement of nicotine-seeking behavior
.
J Neurosci
.
2010
Feb
;
30
(
6
):
2300
10
.
[PubMed]
0270-6474
164.
George
O
,
Ghozland
S
,
Azar
MR
,
Cottone
P
,
Zorrilla
EP
,
Parsons
LH
, et al.
CRF-CRF1 system activation mediates withdrawal-induced increases in nicotine self-administration in nicotine-dependent rats
.
Proc Natl Acad Sci USA
.
2007
Oct
;
104
(
43
):
17198
203
.
[PubMed]
0027-8424
165.
Hollander
JA
,
Lu
Q
,
Cameron
MD
,
Kamenecka
TM
,
Kenny
PJ
.
Insular hypocretin transmission regulates nicotine reward
.
Proc Natl Acad Sci USA
.
2008
Dec
;
105
(
49
):
19480
5
.
[PubMed]
0027-8424
166.
de Lecea
L
,
Jones
BE
,
Boutrel
B
,
Borgland
SL
,
Nishino
S
,
Bubser
M
, et al.
Addiction and arousal: alternative roles of hypothalamic peptides
.
J Neurosci
.
2006
Oct
;
26
(
41
):
10372
5
.
[PubMed]
0270-6474
167.
Plaza-Zabala
A
,
Flores
Á
,
Martín-García
E
,
Saravia
R
,
Maldonado
R
,
Berrendero
F
.
A role for hypocretin/orexin receptor-1 in cue-induced reinstatement of nicotine-seeking behavior
.
Neuropsychopharmacology
.
2013
Aug
;
38
(
9
):
1724
36
.
[PubMed]
0893-133X
168.
Uslaner
JM
,
Winrow
CJ
,
Gotter
AL
,
Roecker
AJ
,
Coleman
PJ
,
Hutson
PH
, et al.
Selective orexin 2 receptor antagonism blocks cue-induced reinstatement, but not nicotine self-administration or nicotine-induced reinstatement
.
Behav Brain Res
.
2014
Aug
;
269
:
61
5
.
[PubMed]
0166-4328
169.
Qi
X
,
Yamada
H
,
Corrie
LW
,
Ji
Y
,
Bauzo
RM
,
Alexander
JC
, et al.
A critical role for the melanocortin 4 receptor in stress-induced relapse to nicotine seeking in rats
.
Addict Biol
.
2015
Mar
;
20
(
2
):
324
35
.
[PubMed]
1355-6215
170.
Engel
JA
,
Jerlhag
E
.
Role of appetite-regulating peptides in the pathophysiology of addiction: implications for pharmacotherapy
.
CNS Drugs
.
2014
Oct
;
28
(
10
):
875
86
.
[PubMed]
1172-7047
171.
Hayes
MR
,
Schmidt
HD
.
GLP-1 influences food and drug reward
.
Curr Opin Behav Sci
.
2016
Jun
;
9
:
66
70
.
[PubMed]
2352-1546
172.
Egecioglu
E
,
Engel
JA
,
Jerlhag
E
.
The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice
.
PLoS One
.
2013
Oct
;
8
(
10
):
e77284
.
[PubMed]
1932-6203
173.
Tuesta
LM
,
Chen
Z
,
Duncan
A
,
Fowler
CD
,
Ishikawa
M
,
Lee
BR
, et al.
GLP-1 acts on habenular avoidance circuits to control nicotine intake
.
Nat Neurosci
.
2017
May
;
20
(
5
):
708
16
.
[PubMed]
1097-6256
174.
Corrigall
WA
,
Coen
KM
,
Adamson
KL
.
Self-administered nicotine activates the mesolimbic dopamine system through the ventral tegmental area
.
Brain Res
.
1994
Aug
;
653
(
1-2
):
278
84
.
[PubMed]
0006-8993
175.
Pons
S
,
Fattore
L
,
Cossu
G
,
Tolu
S
,
Porcu
E
,
McIntosh
JM
, et al.
Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration
.
J Neurosci
.
2008
Nov
;
28
(
47
):
12318
27
.
[PubMed]
0270-6474
176.
Subramaniyan
M
,
Dani
JA
.
Dopaminergic and cholinergic learning mechanisms in nicotine addiction
.
Ann N Y Acad Sci
.
2015
Sep
;
1349
(
1
):
46
63
.
[PubMed]
0077-8923
177.
Gould
TJ
,
Leach
PT
.
Cellular, molecular, and genetic substrates underlying the impact of nicotine on learning
.
Neurobiol Learn Mem
.
2014
Jan
;
107
:
108
32
.
[PubMed]
1074-7427
178.
Mansvelder
HD
,
Mertz
M
,
Role
LW
.
Nicotinic modulation of synaptic transmission and plasticity in cortico-limbic circuits
.
Semin Cell Dev Biol
.
2009
Jun
;
20
(
4
):
432
40
.
[PubMed]
1084-9521
179.
Gray
R
,
Rajan
AS
,
Radcliffe
KA
,
Yakehiro
M
,
Dani
JA
.
Hippocampal synaptic transmission enhanced by low concentrations of nicotine
.
Nature
.
1996
Oct
;
383
(
6602
):
713
6
.
[PubMed]
0028-0836
180.
Radcliffe
KA
,
Dani
JA
.
Nicotinic stimulation produces multiple forms of increased glutamatergic synaptic transmission
.
J Neurosci
.
1998
Sep
;
18
(
18
):
7075
83
.
[PubMed]
0270-6474
181.
Fujii
S
,
Ji
Z
,
Morita
N
,
Sumikawa
K
.
Acute and chronic nicotine exposure differentially facilitate the induction of LTP
.
Brain Res
.
1999
Oct
;
846
(
1
):
137
43
.
[PubMed]
0006-8993
182.
Mansvelder
HD
,
Keath
JR
,
McGehee
DS
.
Synaptic mechanisms underlie nicotine-induced excitability of brain reward areas
.
Neuron
.
2002
Mar
;
33
(
6
):
905
19
.
[PubMed]
0896-6273
183.
Exley
R
,
Cragg
SJ
.
Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission
.
Br J Pharmacol
.
2008
Mar
;
153
(
S1
Suppl 1
):
S283
97
.
[PubMed]
0007-1188
184.
Wooltorton
JR
,
Pidoplichko
VI
,
Broide
RS
,
Dani
JA
.
Differential desensitization and distribution of nicotinic acetylcholine receptor subtypes in midbrain dopamine areas
.
J Neurosci
.
2003
Apr
;
23
(
8
):
3176
85
.
[PubMed]
0270-6474
185.
De Biasi
M
,
Dani
JA
.
Reward, addiction, withdrawal to nicotine
.
Annu Rev Neurosci
.
2011
;
34
(
1
):
105
30
.
[PubMed]
0147-006X
186.
Grieder
TE
,
Herman
MA
,
Contet
C
,
Tan
LA
,
Vargas-Perez
H
,
Cohen
A
, et al.
VTA CRF neurons mediate the aversive effects of nicotine withdrawal and promote intake escalation
.
Nat Neurosci
.
2014
Dec
;
17
(
12
):
1751
8
.
[PubMed]
1097-6256
187.
Corrigall
WA
,
Franklin
KB
,
Coen
KM
,
Clarke
PB
.
The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine
.
Psychopharmacology (Berl)
.
1992
;
107
(
2-3
):
285
9
.
[PubMed]
0033-3158
188.
Tapper
AR
,
McKinney
SL
,
Nashmi
R
,
Schwarz
J
,
Deshpande
P
,
Labarca
C
, et al.
Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization
.
Science
.
2004
Nov
;
306
(
5698
):
1029
32
.
[PubMed]
0036-8075
189.
Grace
AA
,
Bunney
BS
.
Intracellular and extracellular electrophysiology of nigral dopaminergic neurons—3. Evidence for electrotonic coupling
.
Neuroscience
.
1983
Oct
;
10
(
2
):
333
48
.
[PubMed]
0306-4522
190.
Grace
AA
,
Bunney
BS
.
The control of firing pattern in nigral dopamine neurons: burst firing
.
J Neurosci
.
1984
Nov
;
4
(
11
):
2877
90
.
[PubMed]
0270-6474
191.
Hyland
BI
,
Reynolds
JN
,
Hay
J
,
Perk
CG
,
Miller
R
.
Firing modes of midbrain dopamine cells in the freely moving rat
.
Neuroscience
.
2002
;
114
(
2
):
475
92
.
[PubMed]
0306-4522
192.
Phillips
PE
,
Stuber
GD
,
Heien
ML
,
Wightman
RM
,
Carelli
RM
.
Subsecond dopamine release promotes cocaine seeking
.
Nature
.
2003
Apr
;
422
(
6932
):
614
8
.
[PubMed]
0028-0836
193.
Stuber
GD
,
Wightman
RM
,
Carelli
RM
.
Extinction of cocaine self-administration reveals functionally and temporally distinct dopaminergic signals in the nucleus accumbens
.
Neuron
.
2005
May
;
46
(
4
):
661
9
.
[PubMed]
0896-6273
194.
Solecki
W
,
Wickham
RJ
,
Behrens
S
,
Wang
J
,
Zwerling
B
,
Mason
GF
, et al.
Differential role of ventral tegmental area acetylcholine and N-methyl-D-aspartate receptors in cocaine-seeking
.
Neuropharmacology
.
2013
Dec
;
75
:
9
18
.
[PubMed]
0028-3908
195.
Grenhoff
J
,
Aston-Jones
G
,
Svensson
TH
.
Nicotinic effects on the firing pattern of midbrain dopamine neurons
.
Acta Physiol Scand
.
1986
Nov
;
128
(
3
):
351
8
.
[PubMed]
0001-6772
196.
Schilström
B
,
Rawal
N
,
Mameli-Engvall
M
,
Nomikos
GG
,
Svensson
TH
.
Dual effects of nicotine on dopamine neurons mediated by different nicotinic receptor subtypes
.
Int J Neuropsychopharmacol
.
2003
Mar
;
6
(
1
):
1
11
.
[PubMed]
1461-1457
197.
Pidoplichko
VI
,
DeBiasi
M
,
Williams
JT
,
Dani
JA
.
Nicotine activates and desensitizes midbrain dopamine neurons
.
Nature
.
1997
Nov
;
390
(
6658
):
401
4
.
[PubMed]
0028-0836
198.
Lester
RA
,
Dani
JA
.
Time-dependent changes in central nicotinic acetylcholine channel kinetics in excised patches
.
Neuropharmacology
.
1994
Jan
;
33
(
1
):
27
34
.
[PubMed]
0028-3908
199.
Yang
K
,
Buhlman
L
,
Khan
GM
,
Nichols
RA
,
Jin
G
,
McIntosh
JM
, et al.
Functional nicotinic acetylcholine receptors containing α6 subunits are on GABAergic neuronal boutons adherent to ventral tegmental area dopamine neurons
.
J Neurosci
.
2011
Feb
;
31
(
7
):
2537
48
.
[PubMed]
0270-6474
200.
Tolu
S
,
Eddine
R
,
Marti
F
,
David
V
,
Graupner
M
,
Pons
S
, et al.
Co-activation of VTA DA and GABA neurons mediates nicotine reinforcement
.
Mol Psychiatry
.
2013
Mar
;
18
(
3
):
382
93
.
[PubMed]
1359-4184
201.
Hukkanen
J
,
Jacob
P
 3rd
,
Benowitz
NL
.
Metabolism and disposition kinetics of nicotine
.
Pharmacol Rev
.
2005
Mar
;
57
(
1
):
79
115
.
[PubMed]
0031-6997
202.
Rose
JS
,
Dierker
LC
,
Donny
E
.
Nicotine dependence symptoms among recent onset adolescent smokers
.
Drug Alcohol Depend
.
2010
Jan
;
106
(
2-3
):
126
32
.
[PubMed]
0376-8716
203.
Donny
EC
,
Caggiula
AR
,
Mielke
MM
,
Jacobs
KS
,
Rose
C
,
Sved
AF
.
Acquisition of nicotine self-administration in rats: the effects of dose, feeding schedule, and drug contingency
.
Psychopharmacology (Berl)
.
1998
Mar
;
136
(
1
):
83
90
.
[PubMed]
0033-3158
204.
Donny
EC
,
Caggiula
AR
,
Rowell
PP
,
Gharib
MA
,
Maldovan
V
,
Booth
S
, et al.
Nicotine self-administration in rats: estrous cycle effects, sex differences and nicotinic receptor binding
.
Psychopharmacology (Berl)
.
2000
Sep
;
151
(
4
):
392
405
.
[PubMed]
0033-3158
205.
Schwartz
RD
,
Kellar
KJ
.
Nicotinic cholinergic receptor binding sites in the brain: regulation in vivo
.
Science
.
1983
Apr
;
220
(
4593
):
214
6
.
[PubMed]
0036-8075
206.
Flores
CM
,
Rogers
SW
,
Pabreza
LA
,
Wolfe
BB
,
Kellar
KJ
.
A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment
.
Mol Pharmacol
.
1992
Jan
;
41
(
1
):
31
7
.
[PubMed]
0026-895X
207.
Staley
JK
,
Krishnan-Sarin
S
,
Cosgrove
KP
,
Krantzler
E
,
Frohlich
E
,
Perry
E
, et al.
Human tobacco smokers in early abstinence have higher levels of beta2* nicotinic acetylcholine receptors than nonsmokers
.
J Neurosci
.
2006
Aug
;
26
(
34
):
8707
14
.
[PubMed]
0270-6474
208.
Nashmi
R
,
Dickinson
ME
,
McKinney
S
,
Jareb
M
,
Labarca
C
,
Fraser
SE
, et al.
Assembly of alpha4beta2 nicotinic acetylcholine receptors assessed with functional fluorescently labeled subunits: effects of localization, trafficking, and nicotine-induced upregulation in clonal mammalian cells and in cultured midbrain neurons
.
J Neurosci
.
2003
Dec
;
23
(
37
):
11554
67
.
[PubMed]
0270-6474
209.
Mugnaini
M
,
Tessari
M
,
Tarter
G
,
Merlo Pich
E
,
Chiamulera
C
,
Bunnemann
B
.
Upregulation of [3H]methyllycaconitine binding sites following continuous infusion of nicotine, without changes of alpha7 or alpha6 subunit mRNA: an autoradiography and in situ hybridization study in rat brain
.
Eur J Neurosci
.
2002
Nov
;
16
(
9
):
1633
46
.
[PubMed]
0953-816X
210.
Ngolab
J
,
Liu
L
,
Zhao-Shea
R
,
Gao
G
,
Gardner
PD
,
Tapper
AR
.
Functional Upregulation of α4* Nicotinic Acetylcholine Receptors in VTA GABAergic Neurons Increases Sensitivity to Nicotine Reward
.
J Neurosci
.
2015
Jun
;
35
(
22
):
8570
8
.
[PubMed]
0270-6474
211.
Zhou
FM
,
Liang
Y
,
Dani
JA
.
Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum
.
Nat Neurosci
.
2001
Dec
;
4
(
12
):
1224
9
.
[PubMed]
1097-6256
212.
Zhang
T
,
Zhang
L
,
Liang
Y
,
Siapas
AG
,
Zhou
FM
,
Dani
JA
.
Dopamine signaling differences in the nucleus accumbens and dorsal striatum exploited by nicotine
.
J Neurosci
.
2009
Apr
;
29
(
13
):
4035
43
.
[PubMed]
0270-6474
213.
Exley
R
,
Clements
MA
,
Hartung
H
,
McIntosh
JM
,
Cragg
SJ
.
Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens
.
Neuropsychopharmacology
.
2008
Aug
;
33
(
9
):
2158
66
.
[PubMed]
0893-133X
214.
Exley
R
,
Maubourguet
N
,
David
V
,
Eddine
R
,
Evrard
A
,
Pons
S
, et al.
Distinct contributions of nicotinic acetylcholine receptor subunit alpha4 and subunit alpha6 to the reinforcing effects of nicotine
.
Proc Natl Acad Sci USA
.
2011
May
;
108
(
18
):
7577
82
.
[PubMed]
0027-8424
215.
Perez
XA
,
McIntosh
JM
,
Quik
M
.
Long-term nicotine treatment down-regulates α6β2* nicotinic receptor expression and function in nucleus accumbens
.
J Neurochem
.
2013
Dec
;
127
(
6
):
762
71
.
[PubMed]
0022-3042
216.
Exley
R
,
McIntosh
JM
,
Marks
MJ
,
Maskos
U
,
Cragg
SJ
.
Striatal α5 nicotinic receptor subunit regulates dopamine transmission in dorsal striatum
.
J Neurosci
.
2012
Feb
;
32
(
7
):
2352
6
.
[PubMed]
0270-6474
217.
McCallum
SE
,
Parameswaran
N
,
Bordia
T
,
Fan
H
,
McIntosh
JM
,
Quik
M
.
Differential regulation of mesolimbic alpha 3/alpha 6 beta 2 and alpha 4 beta 2 nicotinic acetylcholine receptor sites and function after long-term oral nicotine to monkeys
.
J Pharmacol Exp Ther
.
2006
Jul
;
318
(
1
):
381
8
.
[PubMed]
0022-3565
218.
Schultz
W
.
Responses of midbrain dopamine neurons to behavioral trigger stimuli in the monkey
.
J Neurophysiol
.
1986
Nov
;
56
(
5
):
1439
61
.
[PubMed]
0022-3077
219.
Salminen
O
,
Drapeau
JA
,
McIntosh
JM
,
Collins
AC
,
Marks
MJ
,
Grady
SR
.
Pharmacology of alpha-conotoxin MII-sensitive subtypes of nicotinic acetylcholine receptors isolated by breeding of null mutant mice
.
Mol Pharmacol
.
2007
Jun
;
71
(
6
):
1563
71
.
[PubMed]
0026-895X
220.
Champtiaux
N
,
Han
ZY
,
Bessis
A
,
Rossi
FM
,
Zoli
M
,
Marubio
L
, et al.
Distribution and pharmacology of alpha 6-containing nicotinic acetylcholine receptors analyzed with mutant mice
.
J Neurosci
.
2002
Feb
;
22
(
4
):
1208
17
.
[PubMed]
0270-6474
221.
Wickham
R
,
Solecki
W
,
Rathbun
L
,
McIntosh
JM
,
Addy
NA
.
Ventral tegmental area α6β2 nicotinic acetylcholine receptors modulate phasic dopamine release in the nucleus accumbens core
.
Psychopharmacology (Berl)
.
2013
Sep
;
229
(
1
):
73
82
.
[PubMed]
0033-3158
222.
Brunzell
DH
,
Boschen
KE
,
Hendrick
ES
,
Beardsley
PM
,
McIntosh
JM
.
Alpha-conotoxin MII-sensitive nicotinic acetylcholine receptors in the nucleus accumbens shell regulate progressive ratio responding maintained by nicotine
.
Neuropsychopharmacology
.
2010
Feb
;
35
(
3
):
665
73
.
[PubMed]
0893-133X
223.
Zhang
L
,
Dong
Y
,
Doyon
WM
,
Dani
JA
.
Withdrawal from chronic nicotine exposure alters dopamine signaling dynamics in the nucleus accumbens
.
Biol Psychiatry
.
2012
Feb
;
71
(
3
):
184
91
.
[PubMed]
0006-3223
224.
Toth
E
,
Sershen
H
,
Hashim
A
,
Vizi
ES
,
Lajtha
A
.
Effect of nicotine on extracellular levels of neurotransmitters assessed by microdialysis in various brain regions: role of glutamic acid
.
Neurochem Res
.
1992
Mar
;
17
(
3
):
265
71
.
[PubMed]
0364-3190
225.
Reid
MS
,
Fox
L
,
Ho
LB
,
Berger
SP
.
Nicotine stimulation of extracellular glutamate levels in the nucleus accumbens: neuropharmacological characterization
.
Synapse
.
2000
Feb
;
35
(
2
):
129
36
.
[PubMed]
0887-4476
226.
Lenoir
M
,
Kiyatkin
EA
.
Intravenous nicotine injection induces rapid, experience-dependent sensitization of glutamate release in the ventral tegmental area and nucleus accumbens
.
J Neurochem
.
2013
Nov
;
127
(
4
):
541
51
.
[PubMed]
0022-3042
227.
Brown
RW
,
Kolb
B
.
Nicotine sensitization increases dendritic length and spine density in the nucleus accumbens and cingulate cortex
.
Brain Res
.
2001
Apr
;
899
(
1-2
):
94
100
.
[PubMed]
0006-8993
228.
Lim
WK
,
Wang
K
,
Lefebvre
C
,
Califano
A
.
Comparative analysis of microarray normalization procedures: effects on reverse engineering gene networks
.
Bioinformatics
.
2007
Jul
;
23
(
13
):
i282
8
.
[PubMed]
1367-4803
229.
Salamone
A
,
Zappettini
S
,
Grilli
M
,
Olivero
G
,
Agostinho
P
,
Tomé
AR
, et al.
Prolonged nicotine exposure down-regulates presynaptic NMDA receptors in dopaminergic terminals of the rat nucleus accumbens
.
Neuropharmacology
.
2014
Apr
;
79
:
488
97
.
[PubMed]
0028-3908
230.
Kutlu
MG
,
Gould
TJ
.
Nicotinic modulation of hippocampal cell signaling and associated effects on learning and memory
.
Physiol Behav
.
2016
Mar
;
155
:
162
71
.
[PubMed]
0031-9384
231.
Shingo
AS
,
Kito
S
.
Effects of nicotine on neurogenesis and plasticity of hippocampal neurons
.
J Neural Transm (Vienna)
.
2005
Nov
;
112
(
11
):
1475
8
.
[PubMed]
0300-9564
232.
Scerri
C
,
Stewart
CA
,
Breen
KC
,
Balfour
DJ
.
The effects of chronic nicotine on spatial learning and bromodeoxyuridine incorporation into the dentate gyrus of the rat
.
Psychopharmacology (Berl)
.
2006
Mar
;
184
(
3-4
):
540
6
.
[PubMed]
0033-3158
233.
Van Kampen
JM
,
Eckman
CB
.
Agonist-induced restoration of hippocampal neurogenesis and cognitive improvement in a model of cholinergic denervation
.
Neuropharmacology
.
2010
May
;
58
(
6
):
921
9
.
[PubMed]
0028-3908
234.
Cohen
A
,
Soleiman
MT
,
Talia
R
,
Koob
GF
,
George
O
,
Mandyam
CD
.
Extended access nicotine self-administration with periodic deprivation increases immature neurons in the hippocampus
.
Psychopharmacology (Berl)
.
2015
Jan
;
232
(
2
):
453
63
.
[PubMed]
0033-3158
235.
Abrous
DN
,
Adriani
W
,
Montaron
MF
,
Aurousseau
C
,
Rougon
G
,
Le Moal
M
, et al.
Nicotine self-administration impairs hippocampal plasticity
.
J Neurosci
.
2002
May
;
22
(
9
):
3656
62
.
[PubMed]
0270-6474
236.
Deng
W
,
Aimone
JB
,
Gage
FH
.
New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory?
Nat Rev Neurosci
.
2010
May
;
11
(
5
):
339
50
.
[PubMed]
1471-003X
237.
Bliss
TV
,
Collingridge
GL
.
A synaptic model of memory: long-term potentiation in the hippocampus
.
Nature
.
1993
Jan
;
361
(
6407
):
31
9
.
[PubMed]
0028-0836
238.
Fujii
S
,
Ji
Z
,
Sumikawa
K
.
Inactivation of alpha7 ACh receptors and activation of non-alpha7 ACh receptors both contribute to long term potentiation induction in the hippocampal CA1 region
.
Neurosci Lett
.
2000
Jun
;
286
(
2
):
134
8
.
[PubMed]
0304-3940
239.
Hamid
S
,
Dawe
GS
,
Gray
JA
,
Stephenson
JD
.
Nicotine induces long-lasting potentiation in the dentate gyrus of nicotine-primed rats
.
Neurosci Res
.
1997
Sep
;
29
(
1
):
81
5
.
[PubMed]
0168-0102
240.
Ji
D
,
Lape
R
,
Dani
JA
.
Timing and location of nicotinic activity enhances or depresses hippocampal synaptic plasticity
.
Neuron
.
2001
Jul
;
31
(
1
):
131
41
.
[PubMed]
0896-6273
241.
Tang
J
,
Dani
JA
.
Dopamine enables in vivo synaptic plasticity associated with the addictive drug nicotine
.
Neuron
.
2009
Sep
;
63
(
5
):
673
82
.
[PubMed]
0896-6273
242.
Yakel
JL
,
Shao
Z
.
Functional and molecular characterization of neuronal nicotinic ACh receptors in rat hippocampal interneurons
.
Prog Brain Res
.
2004
;
145
:
95
107
.
[PubMed]
0079-6123
243.
Zhang
TA
,
Tang
J
,
Pidoplichko
VI
,
Dani
JA
.
Addictive nicotine alters local circuit inhibition during the induction of in vivo hippocampal synaptic potentiation
.
J Neurosci
.
2010
May
;
30
(
18
):
6443
53
.
[PubMed]
0270-6474
244.
Kenney
JW
,
Gould
TJ
.
Modulation of hippocampus-dependent learning and synaptic plasticity by nicotine
.
Mol Neurobiol
.
2008
Aug
;
38
(
1
):
101
21
.
[PubMed]
0893-7648
245.
Yakel
JL
.
Nicotinic ACh receptors in the hippocampus: role in excitability and plasticity
.
Nicotine Tob Res
.
2012
Nov
;
14
(
11
):
1249
57
.
[PubMed]
1462-2203
246.
Koob
GF
.
The role of the striatopallidal and extended amygdala systems in drug addiction
.
Ann N Y Acad Sci
.
1999
Jun
;
877
1 ADVANCING FRO
:
445
60
.
[PubMed]
0077-8923
247.
Huang
YY
,
Kandel
ER
,
Levine
A
.
Chronic nicotine exposure induces a long-lasting and pathway-specific facilitation of LTP in the amygdala
.
Learn Mem
.
2008
Aug
;
15
(
8
):
603
10
.
[PubMed]
1072-0502
248.
Khaled
MA
,
Pushparaj
A
,
Di Ciano
P
,
Diaz
J
,
Le Foll
B
.
Dopamine D3 receptors in the basolateral amygdala and the lateral habenula modulate cue-induced reinstatement of nicotine seeking
.
Neuropsychopharmacology
.
2014
Dec
;
39
(
13
):
3049
58
.
[PubMed]
0893-133X
249.
Xue
YX
,
Chen
YY
,
Zhang
LB
,
Zhang
LQ
,
Huang
GD
,
Sun
SC
, et al.
Selective Inhibition of Amygdala Neuronal Ensembles Encoding Nicotine-Associated Memories Inhibits Nicotine Preference and Relapse
.
Biol Psychiatry
.
2017
Dec
;
82
(
11
):
781
93
.
[PubMed]
0006-3223
250.
Funk
D
,
Coen
K
,
Tamadon
S
,
Hope
BT
,
Shaham
Y
,
AD
.
Role of Central Amygdala Neuronal Ensembles in Incubation of Nicotine Craving
.
J Neurosci
.
2016
Aug
;
36
(
33
):
8612
23
.
[PubMed]
0270-6474
251.
Bi
GQ
,
Poo
MM
.
Synaptic modifications in cultured hippocampal neurons: dependence on spike timing, synaptic strength, and postsynaptic cell type
.
J Neurosci
.
1998
Dec
;
18
(
24
):
10464
72
.
[PubMed]
0270-6474
252.
Markram
H
,
Lübke
J
,
Frotscher
M
,
Sakmann
B
.
Regulation of synaptic efficacy by coincidence of postsynaptic APs and EPSPs
.
Science
.
1997
Jan
;
275
(
5297
):
213
5
.
[PubMed]
0036-8075
253.
Couey
JJ
,
Meredith
RM
,
Spijker
S
,
Poorthuis
RB
,
Smit
AB
,
Brussaard
AB
, et al.
Distributed network actions by nicotine increase the threshold for spike-timing-dependent plasticity in prefrontal cortex
.
Neuron
.
2007
Apr
;
54
(
1
):
73
87
.
[PubMed]
0896-6273
254.
Gioanni
Y
,
Rougeot
C
,
Clarke
PB
,
Lepousé
C
,
Thierry
AM
,
Vidal
C
.
Nicotinic receptors in the rat prefrontal cortex: increase in glutamate release and facilitation of mediodorsal thalamo-cortical transmission
.
Eur J Neurosci
.
1999
Jan
;
11
(
1
):
18
30
.
[PubMed]
0953-816X
255.
Vidal
C
,
Changeux
JP
.
Nicotinic and muscarinic modulations of excitatory synaptic transmission in the rat prefrontal cortex in vitro
.
Neuroscience
.
1993
Sep
;
56
(
1
):
23
32
.
[PubMed]
0306-4522
256.
Dickinson
JA
,
Kew
JN
,
Wonnacott
S
.
Presynaptic alpha 7- and beta 2-containing nicotinic acetylcholine receptors modulate excitatory amino acid release from rat prefrontal cortex nerve terminals via distinct cellular mechanisms
.
Mol Pharmacol
.
2008
Aug
;
74
(
2
):
348
59
.
[PubMed]
0026-895X
257.
Pistillo
F
,
Fasoli
F
,
Moretti
M
,
McClure-Begley
T
,
Zoli
M
,
Marks
MJ
, et al.
Chronic nicotine and withdrawal affect glutamatergic but not nicotinic receptor expression in the mesocorticolimbic pathway in a region-specific manner
.
Pharmacol Res
.
2016
Jan
;
103
:
167
76
.
[PubMed]
1043-6618
258.
Ávila-Ruiz
T
,
Carranza
V
,
Gustavo
LL
,
Limón
DI
,
Martínez
I
,
Flores
G
, et al.
Chronic administration of nicotine enhances NMDA-activated currents in the prefrontal cortex and core part of the nucleus accumbens of rats
.
Synapse
.
2014
Jun
;
68
(
6
):
248
56
.
[PubMed]
0887-4476
259.
You
ZB
,
Wang
B
,
Zitzman
D
,
Wise
RA
.
Acetylcholine release in the mesocorticolimbic dopamine system during cocaine seeking: conditioned and unconditioned contributions to reward and motivation
.
J Neurosci
.
2008
Sep
;
28
(
36
):
9021
9
.
[PubMed]
0270-6474
260.
Higgins
GA
,
Silenieks
LB
,
Rossmann
A
,
Rizos
Z
,
Noble
K
,
Soko
AD
, et al.
The 5-HT2C receptor agonist lorcaserin reduces nicotine self-administration, discrimination, and reinstatement: relationship to feeding behavior and impulse control
.
Neuropsychopharmacology
.
2012
Apr
;
37
(
5
):
1177
91
.
[PubMed]
0893-133X
261.
O’Dell
LE
,
Torres
OV
.
A mechanistic hypothesis of the factors that enhance vulnerability to nicotine use in females.
Neuropharmacology,
2014
. 76 Pt B: p. 566-80.
262.
Torres
OV
,
O’Dell
LE
.
Stress is a principal factor that promotes tobacco use in females
.
Prog Neuropsychopharmacol Biol Psychiatry
.
2016
Feb
;
65
:
260
8
.
[PubMed]
0278-5846
263.
Verplaetse
TL
,
Weinberger
AH
,
Smith
PH
,
Cosgrove
KP
,
Mineur
YS
,
Picciotto
MR
, et al.
Targeting the noradrenergic system for gender-sensitive medication development for tobacco dependence
.
Nicotine Tob Res
.
2015
Apr
;
17
(
4
):
486
95
.
[PubMed]
1462-2203
264.
Perkins
KA
.
Smoking cessation in women. Special considerations
.
CNS Drugs
.
2001
;
15
(
5
):
391
411
.
[PubMed]
1172-7047
265.
Perkins
KA
.
Nicotine discrimination in men and women
.
Pharmacol Biochem Behav
.
1999
Oct
;
64
(
2
):
295
9
.
[PubMed]
0091-3057
266.
Lerman
C
,
Kaufmann
V
,
Rukstalis
M
,
Patterson
F
,
Perkins
K
,
Audrain-McGovern
J
, et al.
Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial
.
Ann Intern Med
.
2004
Mar
;
140
(
6
):
426
33
.
[PubMed]
0003-4819
267.
Perkins
KA
.
Acute responses to nicotine and smoking: implications for prevention and treatment of smoking in lower SES women
.
Drug Alcohol Depend
.
2009
Oct
;
104
Suppl 1
:
S79
86
.
[PubMed]
0376-8716
268.
Warren
GW
,
Alberg
AJ
,
Kraft
AS
,
Cummings
KM
.
The 2014 Surgeon General’s report: “The health consequences of smoking—50 years of progress”: a paradigm shift in cancer care
.
Cancer
.
2014
Jul
;
120
(
13
):
1914
6
.
[PubMed]
0008-543X
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.